US20030119759A1 - Recovery of isoflavones from soy molasses - Google Patents

Recovery of isoflavones from soy molasses Download PDF

Info

Publication number
US20030119759A1
US20030119759A1 US10/283,671 US28367102A US2003119759A1 US 20030119759 A1 US20030119759 A1 US 20030119759A1 US 28367102 A US28367102 A US 28367102A US 2003119759 A1 US2003119759 A1 US 2003119759A1
Authority
US
United States
Prior art keywords
isoflavone
health supplement
isoflavones
soy molasses
genistin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/283,671
Inventor
Doyle Waggle
Barbara Bryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archer Daniels Midland Co
Solae LLC
Original Assignee
Protein Technologies International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Technologies International Inc filed Critical Protein Technologies International Inc
Priority to US10/283,671 priority Critical patent/US20030119759A1/en
Assigned to PROTEIN TECHNOLOGIES INTERNATIONAL, INC. reassignment PROTEIN TECHNOLOGIES INTERNATIONAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WAGGLE, DOYLE H., BRYAN, BARBARA A.
Assigned to SOLAE, LLC reassignment SOLAE, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: PROTEIN TECHNOLOGIES INTERNATIONAL, INC.
Publication of US20030119759A1 publication Critical patent/US20030119759A1/en
Assigned to ARCHER-DANIELS-MIDLAND COMPANY reassignment ARCHER-DANIELS-MIDLAND COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOLAE, LLC
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/40Separation, e.g. from natural material; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06Benzopyran radicals
    • C07H17/065Benzo[b]pyrans
    • C07H17/07Benzo[b]pyran-4-ones

Definitions

  • the present invention relates to a health supplement containing at least two isoflavones that is derived from a soy molasses material.
  • Isoflavones occur in a variety of leguminous plants, including vegetable protein materials such as soybeans. These compounds include daidzin, 6′′-OAc daidzin, 6′′-OMal daidzin, daidzein, genistin, 6′′-OAc genistin, 6′′-OMal genistin, genistein, glycitin, 6′′-OAc-glycitin, 6′′-OMal glycitin, glycitein, biochanin A, formononentin, and coumestrol. Typically these compounds are associated with the inherent, bitter flavor of soybeans.
  • the isoflavones in soybean materials include isoflavone glucosides (glucones), isoflavone conjugates and aglucone isoflavones.
  • Isoflavone glucosides have a glucose molecule attached to an isoflavone moiety.
  • Isoflavone conjugates have additional moieties attached to the glucose molecule of an isoflavone glucoside, for example, 6′′-OAc genistin contains an acetate group attached to the six position of the glucose molecule of genistin.
  • Aglucone isoflavones consist solely of an isoflavone moiety.
  • Soy contains three “families” of isoflavone compounds having corresponding glucoside, conjugate, and aglucone members: the genistein family, the daidzein family, and the glycitein family.
  • the genistein family includes the glucoside genistin; the conjugates 6′′-OMal genistin (6′′-malonate ester of genistin) and 6′′-OAc genistin (6′′-acetate ester of genistin); and the aglucone genistein.
  • the daidzein family includes the glucoside daidzin; the conjugates 6′′-OMal daidzin and 6′′-OAc daidzin; and the aglucone daidzein.
  • the glycitein family includes the glucoside glycitin; the conjugate 6′′-OMal glycitin; and the aglucone glycitein.
  • Genistein and daidzein may significantly reduce cardiovascular risk factors. “Plant and Mammalian Estrogen Effects on Plasma Lipids of Female Monkeys”, Circulation, vol. 90, p. 1259 (October 1994). Genistein and daidzein are also thought to reduce the symptoms of conditions caused by reduced or altered levels of endogenous estrogen in women, such as menopause or premenstrual syndrome.
  • aglucone isoflavones may inhibit the growth of human cancer cells, such as breast cancer cells and prostate cancer cells, as described in the following articles: “Genistein Inhibition of the Growth of Human Breast Cancer Cells, Independence from Estrogen Receptors and the Multi-Drug Resistance Gene” by Peterson and Barnes, Biochemical and Biophysical Research, Communications, Vol. 179, No. 1, pp. 661-667, Aug. 30, 1991; “Genistein and Biochanin A Inhibit the Growth of Human Prostrate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation” by Peterson and Barnes, The Prostate, Vol. 22, pp. 335-345 (1993); and “Soybeans Inhibit Mammary Tumors in Models of Breast Cancer” by Barnes, et al., Mutagens and Carcinogens in the Diet, pp. 239-253 (1990).
  • aglucone isoflavones have the following general formula:
  • R 1 , R 2 , R 3 and R 4 may be selected from the group consisting of H, OH and OCH 3 .
  • Genistein has the formula above where R 1 ⁇ OH, R 2 ⁇ H, R 3 ⁇ OH, and R 4 ⁇ OH
  • daidzein has the formula above where R 1 ⁇ OH, R 2 ⁇ H, R 3 ⁇ H, and R 4 ⁇ OH
  • glycitein has the formula above where R 1 ⁇ OH, R 2 ⁇ OCH 3 , R 3 ⁇ H, and R 4 ⁇ OH.
  • the present invention is further directed to isoflavone glucosides and aglucone isoflavones—to the conversion of isoflavones of soy molasses to isoflavone glucosides and aglucone isoflavones, and to the recovery of an isoflavone glucoside enriched material and an aglucone isoflavone enriched material from soy molasses.
  • the present invention is an isoflavone enriched material and a process for recovering the same from a soy molasses material containing isoflavones.
  • the method comprises providing a soy molasses material containing isoflavones, and separating a cake from the soy molasses material at a pH and a temperature sufficient to cause a majority of the isoflavones to be contained in the cake.
  • the pH is about 3.0 to about 6.5 and the temperature is about 0° C. to about 35° C. during the separation.
  • the cake is an isoflavone enriched material.
  • a glucoside enriched isoflavone material is formed from the cake of isoflavone enriched material.
  • An aqueous slurry is formed of the isoflavone enriched material. The slurry is treated at a temperature of about 2° C. to about 120° C. and a pH of about 6 to about 13.5 for a time sufficient to convert isoflavone conjugates in the isoflavone enriched material to isoflavone glucosides.
  • a cake of isoflavone glucoside enriched material may then be separated from the slurry.
  • an aglucone isoflavone enriched material is formed from the cake of isoflavone enriched material.
  • An aqueous slurry is formed of the isoflavone enriched material. The slurry is treated at a temperature of about 2° C. to about 120° C. and a pH of about 6 to about 13.5 for a time sufficient to convert isoflavone conjugates in the isoflavone enriched material to isoflavone glucosides.
  • An enzyme capable of cleaving 1,4-glucoside bonds is contacted with the isoflavone glucosides in the slurry at a temperature of about 5° C. to about 75° C.
  • a cake of aglucone isoflavone enriched material may be separated from the slurry.
  • the present invention is an isoflavone glucoside enriched material and a process for recovering the same from soy molasses.
  • the soy molasses is treated at a temperature of from about 2° C. to about 120° C. and at a pH value of between about 6 to about 13.5 for a time period sufficient to convert isoflavone conjugates contained in the soy molasses to isoflavone glucosides.
  • a cake of isoflavone glucoside enriched material is separated from the soy molasses material at a pH and a temperature sufficient to cause a majority of the isoflavone glucosides to be contained in the cake.
  • the present invention is an aglucone isoflavone enriched material, and a process for recovering the same from soy molasses.
  • the soy molasses is treated at a temperature of from about 2° C. to about 120° C. and at a pH value of between about 6 to about 13.5 for a time period sufficient to convert isoflavone conjugates contained in the soy molasses to isoflavone glucosides.
  • An enzyme capable of cleaving 1,4-glucoside bonds is contacted with the isoflavone glucosides in the soy molasses material at a temperature of about 5° C. to about 75° C.
  • a cake of aglucone isoflavone enriched material is separated from the soy molasses material at a pH and a temperature sufficient to cause a majority of the aglucone isoflavones to be contained in the cake.
  • the starting material of a process of the present invention may be soy molasses.
  • Soy molasses is generally considered to be the soy solubles removed from soy insolubles by washing with alcohol or aqueous acid.
  • Soy solubles included in the soy molasses are primarily carbohydrates, highly soluble protein, and isoflavones.
  • Soy insolubles not included in the soy molasses include vegetable fiber materials, insoluble soy protein, cellulose, and insoluble hemicellulose.
  • Soy molasses is a by-product of many commercial processes involving soybeans or soybean derivatives, such as processes for producing protein concentrate products. Accordingly, soy molasses is produced in large quantities to such an extent that soy molasses is a relatively inexpensive commercially available commodity.
  • the starting material for a process of the present invention may be a soy material which contains isoflavones and carbohydrates from which a soy molasses may be formed.
  • soy materials include, but are not limited to, soy meal, soy flour, soy grits, soy flakes, and mixtures thereof, which preferably have been chemically or mechanically defatted.
  • the starting soy material is extracted or washed with an extractant effective to remove substantial amounts of the isoflavones and carbohydrates present in the soy material. After the extraction or wash, the resulting extract is separated from the insoluble residual soy materials to form a soy molasses.
  • the extractant preferably is selected from an aqueous low molecular weight alcohol solution, or an aqueous solution having a pH at about the isoelectric point of soy protein.
  • preferred aqueous alcohols include aqueous methanol, aqueous ethanol, aqueous isopropyl alcohol, and aqueous propanol, where the alcohol to water ratio of the solution is preferably at least 40:60, and more preferably is at least 60:40, and most preferably falls within a range of from 65:35 to 90:10.
  • a preferred aqueous solution having a pH at about the isoelectric point of soy protein is water adjusted with a suitable acid, preferably a mineral acid such as hydrocholoric acid or sulfuric acid, to a pH of from about 3.5 to about 5.5, more preferably to a pH of from about 4 to about 5, and most preferably to a pH of from about 4.4 to about 4.6.
  • a suitable acid preferably a mineral acid such as hydrocholoric acid or sulfuric acid
  • the soy molasses is produced from defatted soy flakes from which oil has been removed by solvent extraction in a conventional manner.
  • the defatted soy flakes are extracted with water which has been adjusted to an acidic pH, preferably about pH 4 to about pH 5, by the addition of one or more suitable acids such as acetic acid, sulfuric acid, phosphoric acid, hydrochloric acid or any other suitable reagent.
  • the ratio of the acidic extractant to soy flakes is about 10:1 to about 20:1 by weight, and more preferably from about 12:1 to about 16:1.
  • the temperature of the extractant may be elevated above room temperature, preferably between about 32° C. and about 55° C. After the extraction, the soy molasses is removed from the soy insolubles.
  • defatted soy flakes are extracted with aqueous alcohol to produce the soy molasses.
  • the flakes are extracted with about 80% aqueous ethanol at a ratio of about 10:1 to about 20:1 by weight of extractant to soy flakes, and more preferably from about 12:1 to about 16:1 by weight of extractant to soy flakes.
  • the temperature of the alcohol extractant may be elevated above room temperature, preferably from about 32° C. to about 55° C., to improve the efficacy of the extraction.
  • the soy molasses is then removed from the soy insolubles
  • the soy molasses is then condensed.
  • the soy molasses may be condensed by conventional methods for removing a liquid, including, but not limited to, evaporation, preferably under reduced pressure, steam stripping, or distillation.
  • the condensed soy molasses may contain at least 10% solids, by weight, and preferably contains from about 25% to about 60% solids, by weight, and more preferably contains from about 30% to about 50% solids, by weight.
  • condensed soy molasses is typically an aqueous mixture containing about 50% or more solids that comprise about 6% (based on the total weight of the soy molasses) protein, about 3% ash, about 5% fat, and about 36% carbohydrates.
  • Soy molasses material refers to a composition containing soy molasses, a condensed soy molasses, and/or derivatives of soy molasses such as an isoflavone glucoside enriched soy molasses material and an aglucone isoflavone enriched soy molasses material. Accordingly, these terms are used interchangeably herein.
  • An isoflavone enriched material may be recovered from the condensed soy molasses material.
  • the condensed soy molasses material may be diluted with water to a solids content of from about 6% to about 13%, with 13% being most preferred. Dilution of the condensed soy molasses material is not a requirement for the process, however, diluting the relatively thick condensed soy molasses material facilitates processing the material.
  • the condensed soy molasses material preferably diluted, is treated at a pH and a temperature at which a majority of the isoflavones will separate from the liquid fraction of the condensed soy molasses upon performing a separation procedure.
  • the condensed soy molasses material is treated at a pH of about 3.0 to about 6.5 and a temperature of about 0° C. to about 35° C. to maximize the insolubility of the isoflavones in the liquid fraction of the condensed soy molasses.
  • Isoflavones may be separated from the liquid fraction of the condensed soy molasses at pH values outside the preferred range and at temperatures above 35° C., however, these conditions are less preferred since less isoflavones are separated in the separation procedure.
  • the pH of the condensed soy molasses may be adjusted with a suitable conventional acidic or basic reagent, if necessary. It is most preferred that the pH of the condensed soy molasses be adjusted to about 4.5. It is also preferred to chill or cool the condensed soy molasses to a temperature of about 0° C. to about 10° C., and most preferably to a temperature of about 4° C. to about 7° C.
  • the condensed soy molasses material is then subjected to a separation procedure to separate a cake of isoflavone enriched material from the liquid fraction of the condensed soy molasses material.
  • the separation is performed while the soy molasses material is maintained under the previously described pH and temperature conditions.
  • the cake of isoflavone enriched material is separated by centrifuging the soy molasses material and decanting the supernatant from the cake. Centrifugation is preferably performed at about 3,000 to about 10,000 rpm for approximately 30 minutes at about 0° C. to about 10° C.
  • the isoflavone enriched cake may be separated from the soy molasses material by filtration.
  • the filtration is done at the previously described pH and temperature conditions, most preferably at a pH of about 4.5 and a temperature of about 0° C. to about 10° C.
  • the separated cake of isoflavone enriched material contains a significant amount of isoflavones therein.
  • the cake of isoflavone enriched material contains at least 20 mg of isoflavones per gram of cake material, on a dry basis (at least about 2% isoflavones by weight) and more preferably contains from about 20 mg to about 50 mg of isoflavones per gram of cake material (from about 2% to about 5% isoflavones, by weight).
  • a cake of isoflavone glucoside enriched material may be recovered from soy molasses.
  • a soy molasses material is obtained as described above.
  • the soy molasses material be a condensed soy molasses material diluted to a solids content of from about 6% to about 13%, and most preferably about 13%, to facilitate processing the material.
  • a conversion operation is then performed on the soy molasses material to convert isoflavone conjugates in the soy molasses material to isoflavone glucosides.
  • a substantial portion of the isoflavones in the soy molasses material are isoflavone conjugates, therefore the conversion substantially increases the amount of isoflavone glucosides in the soy molasses material.
  • the conversion has been found to be dependent on the pH and the temperature of the soy molasses material.
  • the pH range for conversion of the isoflavone conjugates to isoflavone glucosides in a soy molasses material is from about 6 to about 13.5.
  • the pH of the soy molasses should be adjusted to the desired pH, if necessary, with a suitable base, caustic agent, or basic reagent if the pH is to be raised, or, if the pH is to be lowered, with a suitable acid or acid reagent.
  • the conversion of isoflavone conjugates to isoflavone glucosides has been found to be base catalyzed, and so it is most preferred to utilize a high pH to achieve rapid conversion.
  • the most preferred pH for conversion of the isoflavone conjugates to isoflavone glucosides is a pH of about 9 to about 11.
  • the temperature range for conversion of the isoflavone conjugates to isoflavone glucosides in soy molasses is from about 2° C. to about 120° C.
  • the temperature range at which the conversion readily occurs depends on the pH of the soy molasses material. The inventors have found that the conversion occurs easily at lower temperatures when the pH is relatively high. For example, at a pH of about 11 the conversion occurs rapidly and efficiently at a temperature range of about 5° C. to about 50° C. At a pH of about 9 conversion occurs efficiently within a temperature range of about 45° C. to about 75° C. When the pH of the soy molasses material is relatively low, the conversion occurs at higher temperatures.
  • the conversion occurs within a temperature range of about 80° C. to about 120° C.
  • the conversion is effected at about 35° C. and a pH of about 11.
  • the conversion is effected at a temperature of about 73° C. and a pH of about 9.
  • the time period required for conversion of isoflavone conjugates to isoflavone glucosides depends primarily upon the pH and temperature range utilized in the soy molasses material. Such conversion times typically range from about 15 minutes up to several hours or longer. Conversion occurs more rapidly at a higher pH and at a higher temperature. At a pH of about 9, conversion is substantially complete in about 4 hours to about 6 hours at 73° C. In a most preferred embodiment, the isoflavone conjugates are converted to isoflavone glucosides in about 30 minutes to about 1 hour, preferably about 45 minutes, at a pH of about 11 and at a temperature of about 35° C.
  • the conversion of the isoflavone conjugates to isoflavone glucosides is remarkably efficient, converting at least a majority, and preferably substantially all of the isoflavone conjugates present to isoflavone glucosides.
  • the term a “majority” refers to an extent of conversion of at least about 50%.
  • the term “substantially all” refers to an extent of conversion of at least about 80%, and most preferably at least about 90%.
  • a cake of isoflavone glucoside enriched material may be separated from the soy molasses material.
  • the soy molasses is condensed by conventional means, if the soy molasses material is not already condensed.
  • the condensed soy molasses material is treated at a pH and a temperature at which a majority of the isoflavone glucosides will separate from the liquid fraction of the condensed soy molasses material in a separation procedure.
  • the condensed soy molasses material is maintained at a pH of about 3 to about 6.5, most preferably about 4.5, and at a temperature of about 0° C. to about 35° C., preferably about 0° C. to about 10° C., and most preferably about 4° C. to about 7° C., during the separation process.
  • the pH of the condensed soy molasses material may be adjusted with a suitable conventional acidic or basic reagent, if necessary.
  • the separation may be effected by conventional means for separating solids from a liquid.
  • the isoflavone glucoside enriched cake is preferably separated by centrifugation or filtration as described above with respect to separating an isoflavone enriched cake from the liquid fraction of a condensed soy molasses material.
  • the separated cake of isoflavone glucoside enriched material contains a significant amount of isoflavone glucosides therein.
  • the cake of isoflavone glucoside enriched material contains at least 20 mg of isoflavone glucosides per gram of cake material, on a dry basis (at least about 2% isoflavone glucosides by weight) and more preferably contains from about 20 mg to about 50 mg of isoflavone glucosides per gram of cake material (from about 2% to about 5% isoflavone glucosides, by weight).
  • a cake of aglucone isoflavone enriched material may be recovered from soy molasses.
  • a soy molasses material is obtained as described above, preferably a condensed soy molasses material diluted with water to a solids content of about 6% to about 13%.
  • the soy molasses material is treated to convert the isoflavone conjugates to isoflavone glucosides as described above.
  • An enzymatic conversion operation is then performed on the isoflavone glucoside enriched soy molasses material by contacting a suitable enzyme with isoflavone glucosides in the soy molasses material at a suitable pH and temperature to convert the isoflavone glucosides to aglucone isoflavones.
  • the two-step conversion process effectively converts substantially all of the isoflavone conjugates and isoflavone glucosides in the soy molasses material to aglucone isoflavones, substantially increasing the amount of aglucone isoflavones in the soy molasses material.
  • the conversion of isoflavone glucosides to aglucone isoflavones has been found to be dependent on a variety of factors including the type of enzymes present in the soy molasses material, distribution of enzyme concentrations, activities of the enzymes, and the pH and temperature of the soy molasses material during the conversion.
  • the enzymes required to effect the conversion are enzymes capable of cleaving the glucosidic linkage between the isoflavone moiety and the glucose molecule of the isoflavone glucosides.
  • the enzymes are saccharidase or gluco-amylase enzymes capable of cleaving 1,4-glucoside bonds.
  • the enzymes may be inherently present in the soy molasses material, or may be commercially available enzymes which are added to the soy molasses material. Inherently present enzymes are referred to herein as “residual” enzymes, and enzymes that are added to the soy molasses material are referred to herein as “supplemental” enzymes.
  • Sufficient enzyme should be present in the soy molasses material to convert at least a majority, and preferably substantially all, of the isoflavone glucosides to aglucone isoflavones.
  • supplemental enzymes should be added to the soy molasses material.
  • supplemental enzymes are added to the soy molasses material regardless of whether sufficient residual enzymes are present in the soy molasses material since addition of supplemental enzymes dramatically decreases the time necessary to effect substantially complete conversion of the glucosides to aglucones. If supplemental enzymes are added, the supplemental enzymes should be added so that the total concentration of enzyme present is about 0.1% to about 10% by weight of the solids in the soy molasses material on a dry basis.
  • Supplemental enzymes are selected based on optimum activity at selected pH and temperature conditions, and cost effectiveness.
  • the supplemental enzymes are enzymes capable of cleaving the bond between the isoflavone moiety and the glucose molecule of the isoflavone glucosides, such as saccharidase and gluco-amylase enzymes capable of cleaving 1,4-glucoside bonds.
  • Preferred supplemental enzymes are commercially available alpha-and beta-glucosidase enzymes, beta-galactosidase enzymes, gluco-amylase enzymes, and pectinase enzymes.
  • enzymes such as Biopectinase 100L (which is preferably utilized at a pH range of from about 3 to about 6), Biopectinase 300L (optimum pH range from about 3 to about 6), Biopectinase OK 70L (optimum pH range from about 3 to about 6), Biolactase 30,000 (optimum pH range from about 3 to about 6) Neutral Lactase (optimum pH range from about 6 to about 8), all of which are available from Quest International, 1833 57th Street, Post Office Box 3917, Sarasota, Fla. 34243.
  • Biopectinase 100L which is preferably utilized at a pH range of from about 3 to about 6
  • Biopectinase 300L optimum pH range from about 3 to about 6
  • Biopectinase OK 70L optimum pH range from about 3 to about 6
  • Biolactase 30,000 optimum pH range from about 3 to about 6
  • Neutral Lactase optimum pH
  • Lactase F which is preferably utilized at a pH range of from about 4 to about 6
  • Lactase 50,000 optimum pH range from about 4 to about 6
  • Other particularly preferred supplemental enzymes include G-Zyme G990 (optimum pH from about 4 to about 6) and Enzeco Fungal Lactase Concentrate (optimum pH from about 4 to about 6) available from Enzyme Development Corporation, 2 Penn Plaza, Suite 2439, New York, N.Y.
  • Lactozyme 3000L which preferably is utilized at a pH range from about 6 to about 8
  • Alpha-Gal 600L which preferably is utilized at a pH range of from about 4 to about 6.5
  • Novo Nordisk Bioindustrials, Inc. 33 Turner Road, Danbury, Conn. 06813
  • Maxilact L2000 which is preferably utilized at a pH range of from about 4 to about 6
  • Gist Brocades Food Ingredients, Inc. King of Prussia, Pa., 19406
  • Neutral Lactase which is preferably utilized at a pH range of from about 6 to about 8
  • Pfizer Food Science Group 205 East 42nd Street, New York, N.Y. 10017.
  • the pH range for conversion of the isoflavone glucosides to aglucone isoflavones is from about 3 to about 9.
  • the pH that is utilized depends primarily upon the type of enzyme used, and should be selected accordingly.
  • the residual enzyme is active within a pH range of about 7 to about 9, although it is believed that the pH of the soy molasses material is lowered during the course of the conversion.
  • the supplemental enzymes are active within an optimum pH range specified by the manufacturer of the enzyme, as shown above for several specific enzymes. Typically the supplemental enzymes are active either in a neutral pH range from about 6 to about 8, or in an acidic pH range from about 3 to about 6.
  • the pH of the soy molasses material may be adjusted to a desired value for conducting the conversion of isoflavone glucosides to aglucone isoflavones.
  • the pH is reduced from the relatively high or basic pH required to convert the isoflavone conjugates to isoflavone glucosides by the addition of one or more suitable acids such as acetic acid, sulfuric acid, phosphoric acid, hydrochloric acid, or any other suitable reagent.
  • the temperature range of the soy molasses material for the conversion of glucosides to aglucones is from about 5° C. to about 75° C.
  • the temperature significantly affects the activity of the enzymes, and therefore, the rate of conversion.
  • the supplemental enzymes may be active above 70° C., for example Alpha-Gal 600L is active at 75° C., however, it is preferred to conduct the conversion at lower temperatures to avoid enzyme deactivation. In a preferred embodiment, the conversion is effected between about 35° C. and about 45° C.
  • the time required for conversion of the glucosides to aglucones depends upon enzyme-related factors, particularly concentration, and the temperature and pH of the system. In most instances it is possible to achieve substantially complete conversion within 24 hours, however, it is preferred that supplemental enzyme be added to dramatically increase the rate of the reaction.
  • the selected supplemental enzyme, enzyme concentration, pH and temperature preferably cause substantially complete conversion within about 2 hours, and most preferably within about 1 hour.
  • the conversion of the isoflavone glucosides to aglucone isoflavones is remarkably efficient, converting at least a majority, and preferably substantially all of the glucosides present to aglucones.
  • the term “a majority” refers to an extent of conversion of at least about 50%.
  • the term “substantially all” refers to an extent of conversion of at least about 80%, and most preferably at least about 90%.
  • the soy molasses material is condensed as described above, if the soy molasses material has not already been condensed.
  • a cake of aglucone isoflavone enriched material may be separated from the liquid fraction of the condensed soy molasses material.
  • the soy molasses material is treated at a pH and a temperature at which a majority of the aglucone isoflavones will separate from the liquid fraction of the condensed soy molasses material in a separation procedure.
  • the condensed soy molasses material is maintained at a pH of about 3 to about 6.5, most preferably about 4.5, and at a temperature of about 0° C. to about 35° C., preferably about 0° C. to about 10° C., and most preferably about 4° C. to about 7° C., during the separation process.
  • the pH of the condensed soy molasses material may be adjusted with a suitable conventional acidic or basic reagent, if necessary.
  • the separation may be effected by conventional means for separating solids from a liquid.
  • the aglucone isoflavone enriched cake is preferably separated by centrifugation or filtration as described above with respect to separating an isoflavone enriched cake from the liquid fraction of a condensed soy molasses material.
  • the separated cake of aglucone isoflavone enriched material contains a significant amount of aglucone isoflavones therein.
  • the cake of aglucone isoflavone enriched material contains at least 20 mg of aglucone isoflavones per gram of cake material, on a dry basis (at least about 2% aglucone isoflavones by weight) and more preferably contains from about 20 mg to about 50 mg of aglucone isoflavones per gram of cake material (from about 2% to about 5% aglucone isoflavones, by weight).
  • An aglucone isoflavone enriched material may also be produced from an isoflavone enriched material recovered from soy molasses, where the process for recovering an isoflavone enriched material from soy molasses is described above. Water is added to the recovered cake of isoflavone enriched material to form a slurry of the isoflavone enriched material. Preferably the slurry is diluted to about 6% to about 13% solids, although a higher solids content may be used.
  • Isoflavone conjugates in the slurry are then converted to isoflavone glucosides by treating the slurry under the same conditions described above with respect to converting isoflavone conjugates to isoflavone glucosides in soy molasses.
  • the slurry is treated at a pH of about 6 to about 13.5, preferably about pH 9 to about pH 11, and a temperature of about 2° C. to about 120° C. for a period of about 15 minutes to several hours.
  • Most preferably the slurry is treated at a pH of about 11 and a temperature of about 5° C.
  • an isoflavone glucoside enriched material may be separated from the slurry in a manner similar to the separation of an isoflavone enriched material from soy molasses described above.
  • Isoflavone glucosides in the slurry are then converted to aglucone isoflavones under the same conditions described above with respect to converting isoflavone glucosides to aglucone isoflavones in a soy molasses material.
  • the isoflavone glucosides in the slurry are contacted with an enzyme capable of cleaving the glucosidic linkage between the isoflavone moiety and the glucose molecule of the isoflavone glucosides under suitable pH and temperature conditions for a period of time sufficient to convert the isoflavone glucosides to aglucone isoflavones.
  • An aglucone isoflavone enriched material may be separated from the slurry in a manner similar to the separation of an isoflavone enriched material from soy molasses described above.
  • An aglucone isoflavone enriched material may also be produced from an isoflavone glucoside enriched material recovered from a soy molasses material, where the process for recovering an isoflavone glucoside enriched material from a soy molasses material is described above.
  • Water is added to the recovered cake of isoflavone glucoside enriched material to form a slurry of the isoflavone glucoside enriched material.
  • the slurry is diluted to about 6% to about 13% solids, although a higher solids content may be used.
  • the isoflavone glucosides in the slurry are converted to aglucone isoflavones in the same manner described above with respect to the isoflavone glucoside enriched slurry formed from an isoflavone enriched slurry.
  • An aglucone isoflavone enriched material may be separated from the slurry after the conversion in a manner similar to the separation of an isoflavone enriched material from soy molasses described above.
  • soy materials include the genistein, daidzein, and glycitein “families” of isoflavones having corresponding glucoside, conjugate, and aglucone members, where the genistein family contains the conjugates 6′′-OMal genistin, 6′′-OAc genistin, the glucoside genistin, and the aglucone genistein; the daidzein family contains the conjugates 6′′-OMal daidzin, 6′′-OAc daidzin, the glucoside daidzin, and the aglucone daidzein; and the glycitein family includes the conjugate 6′′-OMal glycitin, the glucoside glycitin, and the aglucone glycitein.
  • the relative concentrations of isoflavones are measured either as a total concentration of an isoflavone family, or as individual percentages of each isoflavone in a family of isoflavones.
  • Soy molasses is analyzed for the total concentration of all forms of isoflavones present.
  • Samples of the soy molasses are diluted with water to a solids content of 28% (1:2 dilution), 13.7% (1:4 dilution), and 6.6% (1:8 dilution). All samples are pH adjusted to 4.5.
  • the treated samples are then centrifiged at a rate of between 3000 rpm for 30 minutes to separate and produce liquid whey and cake portions from the samples.
  • One set of samples is centrifuged at a temperature of 0.6° C.
  • Samples having 28% and 13.7% soy molasses solids are centrifuged at a temperature of 60° C. for comparison with samples having the same concentration of soy molasses solids that are separated at 0.6° C.
  • the resulting liquid and cake portions of the samples are analyzed for the total concentration of all forms of isoflavones present.
  • Table 1 sets forth the concentrations of isoflavones in the various cake and liquid fractions obtained from the previously described testing. The indicated totals are the totals of all forms of the particular isoflavone including conjugates, glucoside, and aglucone forms expressed in mg of isoflavone per gram of cake or liquid fraction solids.
  • TABLE 1 Total Total Total Genistein Daidzein Glycitein (family) (family) (family) Sample mg/g mg/g mg/g Soy Molasses 6.1 4.8 1.0 Starting Material Not separated 1:2 Dilution (28% solids) 2.8 3.0 0.6 Whey separated at 0.6° C. 1:2 Dilution 16.9 10.9 1.9 Cake separated at 0.6° C.
  • the concentration of isoflavones is significantly higher in the cake than in soy molasses starting material and much higher than the concentration of isoflavones in the liquid whey fraction solids.
  • the samples separated at 0.6° C. contained a higher concentration of isoflavones in the cake than corresponding samples separated at 60° C., which had higher concentrations of isoflavones in the whey fraction solids.
  • Soy molasses starting material is analyzed for concentration of individual isoflavone compounds.
  • Two samples of the soy molasses material are made by diluting the soy molasses with water in the following ratios: 1:4(100 g of molasses+300 g water); and 1:8(50 g of molasses+350 g water).
  • the pH of the samples is adjusted to 11, and the temperature of the samples is held at 35° C. for 30 minutes.
  • the pH of the samples is then adjusted to 4.5 and the temperature is adjusted to 4° C.
  • the samples are centrifuged at 10,000 rpm at 4° C. to separate the molasses samples into a cake and a liquid whey.
  • the whey and the cake are analyzed for concentration of individual isoflavone compounds.
  • Table 2 illustrates the change in the proportions between the various forms of isoflavones resulting from the conversion of isoflavone conjugates to isoflavone glucosides as compared to the soy molasses starting material. Isoflavone concentrations are indicated as parts per million(ppm) within the sample, and as percentages of the total amount of the particular isoflavone (the total of the conjugate, glucoside, and aglucone forms) within the liquid or cake portion.
  • Soy molasses starting material is diluted 1:4 with water and is analyzed for concentration of individual isoflavone compounds. The pH of the molasses is then adjusted to 11. The soy molasses is held at room temperature for 1 hour to produce a glucoside enriched soy molasses material. The glucoside enriched soy molasses material is analyzed for concentration of individual isoflavone compounds. Four samples are prepared from the glucoside enriched soy molasses material after the pH of the material is adjusted to 4.5.
  • Each sample is inoculated with an enzyme, where the following enzymes are added to the samples, respectively, at 10% by weight of the molasses solids in each sample: G-Zyme 990, Biopectinase 100L, Lactase 50,000, and Alpha-Gal 600L.
  • the samples are then treated at 50° C. for 6 hours to form an aglucone isoflavone enriched soy molasses material.
  • the aglucone isoflavone enriched soy molasses is then analyzed for isoflavone content.
  • Table 3 illustrates the distribution between the various forms of isoflavones resulting from the previously described testing. Isoflavone concentrations are indicated as parts per million(ppm) within the sample, and as percentages of the total amount of the particular isoflavone (the total of the conjugate, glucoside, and aglucone forms).
  • the aglucone isoflavone content of the enzymatically treated samples is significantly higher than the soy molasses and the glucoside enriched soy molasses material, indicating that the enzymatic treatment converted substantial amounts of glucoside isoflavones to aglucone isoflavones.
  • Selection of the proper enzyme, enzyme concentration, pH and temperature for the conversion permits conversion of substantially all of the isoflavone glucosides to aglucone isoflavones, as demonstrated by the isoflavone distribution in the Lactase 50,000 and Alpha-Gal 600L samples.
  • the isoflavone content of an isoflavone enriched material, an isoflavone glucoside enriched material, and an aglucone isoflavone enriched material is examined and the distribution of the isoflavones in the materials is compared.
  • Soy molasses is diluted to a 1:4 ratio with water.
  • a sample of the diluted soy molasses is adjusted to a pH of 4.5, is chilled to a temperature of 0.6° C. in an ice bath for 30 minutes, and is centrifuged at a rate of 3000 rpm for 30 minutes to separate a cake of isoflavone enriched material.
  • the remaining diluted soy molasses is then adjusted to a pH of 11 with sodium hydroxide and is treated at 50° C. for 1 hour to convert isoflavone conjugates in the molasses to isoflavone glucosides.
  • a sample of the glucoside enriched molasses is adjusted to a pH of 4.5, is chilled to a temperature of 0.6° C. in an icebath for 30 minutes, and is centrifuged at a rate of 3000 rpm for 30 minutes to separate a cake of isoflavone glucoside enriched material.
  • the remaining isoflavone glucoside enriched soy molasses material is adjusted to pH 4.5, and the enzyme G-Zyme 990 is added to the material at a concentration of 2.6 g enzyme/100 g of molasses material.
  • the enzyme and the isoflavone glucoside enriched soy molasses material are then treated at 50° C. for 18 to 20 hours to convert the isoflavone glucosides to aglucone isoflavones.
  • a sample of the aglucone isoflavone enriched soy molasses material is chilled to a temperature of 0.6° C.
  • Table 4 shows the distribution of the isoflavones in the cakes of isoflavone enriched material, isoflavone glucoside enriched material, and aglucone isoflavone enriched material. Isoflavone distribution is indicated as percentages of the total amount of the particular isoflavone (the total of the conjugate, glucoside, and aglucone forms).
  • the effectiveness of the conversion steps can be seen in the isoflavone distribution of the materials.
  • the isoflavone glucoside enriched material contains significantly higher amounts of isoflavone glucosides than the isoflavone enriched material and the aglucone isoflavone material, having an isoflavone content which is comprised of almost entirely isoflavone glucosides.
  • the aglucone isoflavone enriched material contains significantly higher amounts of aglucone isoflavones than the isoflavone glucoside enriched material and the isoflavone enriched material, having an isoflavone content which is comprised of almost entirely aglucone isoflavones.
  • the extracted isoflavones are separated by HPLC (High Performance Liquid Chromatography)using a Hewlett Packard C18 Hypersil reverse phase column.
  • HPLC High Performance Liquid Chromatography
  • the isoflavones are injected onto the column and eluted with a solvent gradient starting with 88% methanol, 10% water, and 2% glacial acetic acid and ending with 98% methanol and 2% glacial acetic acid.
  • Quantification is achieved by using pure standards (genistin, genistein, daidzin and daidzein) obtained from Indofine Chemical Company, Sommerville, N.J.
  • Response factors integrated area/concentration
  • response factors are assumed to be that of the parent molecule but corrected for molecular weight difference.
  • the response factor for glycitin is assumed to be that for genistin corrected for molecular weight difference. This method provides the quantities of each individual isoflavone.
  • total genistein, total daidzein and total glycitein can be calculated, and represent the aggregate weight of these compounds if all the conjugated forms are converted to their respective unconjugated forms. These totals can also be measured directly by a method using acid hydrolysis to convert the conjugated forms.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Pyrane Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A health supplement composition is disclosed. The health supplement composition contains a solid health supplement material that is separated from a soy molasses material. The solid health supplement material contains at least least two isoflavones.

Description

  • This application is a divisional of patent application Ser. No. 10/016,461 filed on Oct. 19, 2001 which is a divisonal application of patent application Ser. No. 09/204,808 filed on Dec. 3. 1998, now U.S. Pat. No. 6,323,018, which is a continuation of patent application Ser. No. 09/086,658 filed on May 29, 1998, now U.S Pat. No. 5,919,921, which is a continuation-in-part of patent application Ser. No. 08/661,845 filed on Jun. 11, 1996, now U.S. Pat. No. 5,821,361.[0001]
  • FIELD OF THE INVENTION
  • The present invention relates to a health supplement containing at least two isoflavones that is derived from a soy molasses material. [0002]
  • BACKGROUND OF THE INVENTION
  • Isoflavones occur in a variety of leguminous plants, including vegetable protein materials such as soybeans. These compounds include daidzin, 6″-OAc daidzin, 6″-OMal daidzin, daidzein, genistin, 6″-OAc genistin, 6″-OMal genistin, genistein, glycitin, 6″-OAc-glycitin, 6″-OMal glycitin, glycitein, biochanin A, formononentin, and coumestrol. Typically these compounds are associated with the inherent, bitter flavor of soybeans. [0003]
  • The isoflavones in soybean materials include isoflavone glucosides (glucones), isoflavone conjugates and aglucone isoflavones. Isoflavone glucosides have a glucose molecule attached to an isoflavone moiety. Isoflavone conjugates have additional moieties attached to the glucose molecule of an isoflavone glucoside, for example, 6″-OAc genistin contains an acetate group attached to the six position of the glucose molecule of genistin. Aglucone isoflavones consist solely of an isoflavone moiety. [0004]
  • Soy contains three “families” of isoflavone compounds having corresponding glucoside, conjugate, and aglucone members: the genistein family, the daidzein family, and the glycitein family. The genistein family includes the glucoside genistin; the conjugates 6″-OMal genistin (6″-malonate ester of genistin) and 6″-OAc genistin (6″-acetate ester of genistin); and the aglucone genistein. The daidzein family includes the glucoside daidzin; the conjugates 6″-OMal daidzin and 6″-OAc daidzin; and the aglucone daidzein. The glycitein family includes the glucoside glycitin; the conjugate 6″-OMal glycitin; and the aglucone glycitein. [0005]
  • In the production of commercial products, such as vegetable protein concentrates, the focus has been to remove these materials. For example, in a conventional process for the production of a soy protein concentrate in which soy flakes are extracted with an aqueous acid or an aqueous alcohol to remove water soluble materials from the soy flakes, much of the isoflavones are solubilized in the extract. The extract of water soluble materials, including the isoflavones, is soy molasses. The soy molasses is a byproduct material in the production of soy protein concentrate which is typically discarded. Soy molasses, therefore, is an inexpensive and desirable source of isoflavones, provided that the isoflavones can be separated from the soy molasses. [0006]
  • It has recently been recognized that the isoflavones contained in vegetable protein materials such as soybeans have medicinal value. The aglucone isoflavones are of particular interest. Genistein and daidzein may significantly reduce cardiovascular risk factors. “Plant and Mammalian Estrogen Effects on Plasma Lipids of Female Monkeys”, [0007] Circulation, vol. 90, p. 1259 (October 1994). Genistein and daidzein are also thought to reduce the symptoms of conditions caused by reduced or altered levels of endogenous estrogen in women, such as menopause or premenstrual syndrome. Further, it has recently been recognized that aglucone isoflavones may inhibit the growth of human cancer cells, such as breast cancer cells and prostate cancer cells, as described in the following articles: “Genistein Inhibition of the Growth of Human Breast Cancer Cells, Independence from Estrogen Receptors and the Multi-Drug Resistance Gene” by Peterson and Barnes, Biochemical and Biophysical Research, Communications, Vol. 179, No. 1, pp. 661-667, Aug. 30, 1991; “Genistein and Biochanin A Inhibit the Growth of Human Prostrate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation” by Peterson and Barnes, The Prostate, Vol. 22, pp. 335-345 (1993); and “Soybeans Inhibit Mammary Tumors in Models of Breast Cancer” by Barnes, et al., Mutagens and Carcinogens in the Diet, pp. 239-253 (1990).
  • The aglucone isoflavones have the following general formula: [0008]
    Figure US20030119759A1-20030626-C00001
  • wherein, R[0009] 1, R2, R3 and R4 may be selected from the group consisting of H, OH and OCH3.
  • Genistein has the formula above where R[0010] 1═OH, R2═H, R3═OH, and R4═OH, daidzein has the formula above where R1═OH, R2═H, R3═H, and R4═OH, and glycitein has the formula above where R1═OH, R2═OCH3, R3═H, and R4═OH.
  • It is therefore to the isoflavones and to the recovery of an isoflavone enriched material from soy molasses to which the present invention is directed. The present invention is further directed to isoflavone glucosides and aglucone isoflavones—to the conversion of isoflavones of soy molasses to isoflavone glucosides and aglucone isoflavones, and to the recovery of an isoflavone glucoside enriched material and an aglucone isoflavone enriched material from soy molasses. [0011]
  • A general process for converting vegetable protein isoflavone conjugates to aglucone isoflavones is known, and is provided in the currently pending application U.S. Ser. No. 08/477,102 filed Jun. 7, 1995 owned by the assignee of the present application. [0012]
  • Other processes are known in the art for converting isoflavone glucosides to aglucone isoflavones, such as described in Japanese Patent Application 258,669 to Obata, et al. Such processes do not provide for the recovery of an isoflavone enriched material from soy molasses. Such processes also do not provide for the conversion of isoflavone conjugates to isoflavone glucosides or to aglucone isoflavones. Furthermore, these processes achieve only a moderate extent of conversion of isoflavone glucosides to aglucone isoflavones, and require a substantial period of time to effect this moderate extent conversion. [0013]
  • It is therefore an object of the present invention to provide an isoflavone enriched material and a process for producing the same from soy molasses. [0014]
  • It is a further object of the present invention to provide an isoflavone glucoside enriched material and a process for producing the same from soy molasses. [0015]
  • It is still a further object of the present invention to provide an aglucone isoflavone enriched material and a process for producing the same from soy molasses. [0016]
  • SUMMARY OF THE INVENTION
  • The present invention is an isoflavone enriched material and a process for recovering the same from a soy molasses material containing isoflavones. The method comprises providing a soy molasses material containing isoflavones, and separating a cake from the soy molasses material at a pH and a temperature sufficient to cause a majority of the isoflavones to be contained in the cake. Preferably the pH is about 3.0 to about 6.5 and the temperature is about 0° C. to about 35° C. during the separation. The cake is an isoflavone enriched material. [0017]
  • In one embodiment, a glucoside enriched isoflavone material is formed from the cake of isoflavone enriched material. An aqueous slurry is formed of the isoflavone enriched material. The slurry is treated at a temperature of about 2° C. to about 120° C. and a pH of about 6 to about 13.5 for a time sufficient to convert isoflavone conjugates in the isoflavone enriched material to isoflavone glucosides. A cake of isoflavone glucoside enriched material may then be separated from the slurry. [0018]
  • In another embodiment, an aglucone isoflavone enriched material is formed from the cake of isoflavone enriched material. An aqueous slurry is formed of the isoflavone enriched material. The slurry is treated at a temperature of about 2° C. to about 120° C. and a pH of about 6 to about 13.5 for a time sufficient to convert isoflavone conjugates in the isoflavone enriched material to isoflavone glucosides. An enzyme capable of cleaving 1,4-glucoside bonds is contacted with the isoflavone glucosides in the slurry at a temperature of about 5° C. to about 75° C. and a pH of about 3 to about 9 for a time sufficient to convert the isoflavone glucosides to aglucone isoflavones. A cake of aglucone isoflavone enriched material may be separated from the slurry. [0019]
  • In another aspect, the present invention is an isoflavone glucoside enriched material and a process for recovering the same from soy molasses. The soy molasses is treated at a temperature of from about 2° C. to about 120° C. and at a pH value of between about 6 to about 13.5 for a time period sufficient to convert isoflavone conjugates contained in the soy molasses to isoflavone glucosides. A cake of isoflavone glucoside enriched material is separated from the soy molasses material at a pH and a temperature sufficient to cause a majority of the isoflavone glucosides to be contained in the cake. [0020]
  • In another aspect, the present invention is an aglucone isoflavone enriched material, and a process for recovering the same from soy molasses. The soy molasses is treated at a temperature of from about 2° C. to about 120° C. and at a pH value of between about 6 to about 13.5 for a time period sufficient to convert isoflavone conjugates contained in the soy molasses to isoflavone glucosides. An enzyme capable of cleaving 1,4-glucoside bonds is contacted with the isoflavone glucosides in the soy molasses material at a temperature of about 5° C. to about 75° C. and a pH of about 3 to about 9 for a time period sufficient to convert the isoflavone glucosides to aglucone isoflavones. A cake of aglucone isoflavone enriched material is separated from the soy molasses material at a pH and a temperature sufficient to cause a majority of the aglucone isoflavones to be contained in the cake. [0021]
  • DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
  • The starting material of a process of the present invention may be soy molasses. Soy molasses is generally considered to be the soy solubles removed from soy insolubles by washing with alcohol or aqueous acid. Soy solubles included in the soy molasses are primarily carbohydrates, highly soluble protein, and isoflavones. Soy insolubles not included in the soy molasses include vegetable fiber materials, insoluble soy protein, cellulose, and insoluble hemicellulose. Soy molasses is a by-product of many commercial processes involving soybeans or soybean derivatives, such as processes for producing protein concentrate products. Accordingly, soy molasses is produced in large quantities to such an extent that soy molasses is a relatively inexpensive commercially available commodity. [0022]
  • Alternatively, the starting material for a process of the present invention may be a soy material which contains isoflavones and carbohydrates from which a soy molasses may be formed. Such soy materials include, but are not limited to, soy meal, soy flour, soy grits, soy flakes, and mixtures thereof, which preferably have been chemically or mechanically defatted. [0023]
  • The starting soy material is extracted or washed with an extractant effective to remove substantial amounts of the isoflavones and carbohydrates present in the soy material. After the extraction or wash, the resulting extract is separated from the insoluble residual soy materials to form a soy molasses. The extractant preferably is selected from an aqueous low molecular weight alcohol solution, or an aqueous solution having a pH at about the isoelectric point of soy protein. For example, preferred aqueous alcohols include aqueous methanol, aqueous ethanol, aqueous isopropyl alcohol, and aqueous propanol, where the alcohol to water ratio of the solution is preferably at least 40:60, and more preferably is at least 60:40, and most preferably falls within a range of from 65:35 to 90:10. A preferred aqueous solution having a pH at about the isoelectric point of soy protein is water adjusted with a suitable acid, preferably a mineral acid such as hydrocholoric acid or sulfuric acid, to a pH of from about 3.5 to about 5.5, more preferably to a pH of from about 4 to about 5, and most preferably to a pH of from about 4.4 to about 4.6. [0024]
  • In a preferred embodiment, the soy molasses is produced from defatted soy flakes from which oil has been removed by solvent extraction in a conventional manner. The defatted soy flakes are extracted with water which has been adjusted to an acidic pH, preferably about pH 4 to about pH 5, by the addition of one or more suitable acids such as acetic acid, sulfuric acid, phosphoric acid, hydrochloric acid or any other suitable reagent. Preferably the ratio of the acidic extractant to soy flakes is about 10:1 to about 20:1 by weight, and more preferably from about 12:1 to about 16:1. To improve the efficacy of the extraction, the temperature of the extractant may be elevated above room temperature, preferably between about 32° C. and about 55° C. After the extraction, the soy molasses is removed from the soy insolubles. [0025]
  • In another embodiment, defatted soy flakes are extracted with aqueous alcohol to produce the soy molasses. Preferably, the flakes are extracted with about 80% aqueous ethanol at a ratio of about 10:1 to about 20:1 by weight of extractant to soy flakes, and more preferably from about 12:1 to about 16:1 by weight of extractant to soy flakes. The temperature of the alcohol extractant may be elevated above room temperature, preferably from about 32° C. to about 55° C., to improve the efficacy of the extraction. The soy molasses is then removed from the soy insolubles [0026]
  • The soy molasses is then condensed. The soy molasses may be condensed by conventional methods for removing a liquid, including, but not limited to, evaporation, preferably under reduced pressure, steam stripping, or distillation. The condensed soy molasses may contain at least 10% solids, by weight, and preferably contains from about 25% to about 60% solids, by weight, and more preferably contains from about 30% to about 50% solids, by weight. For example, condensed soy molasses is typically an aqueous mixture containing about 50% or more solids that comprise about 6% (based on the total weight of the soy molasses) protein, about 3% ash, about 5% fat, and about 36% carbohydrates. “Soy molasses material” as that term is used herein refers to a composition containing soy molasses, a condensed soy molasses, and/or derivatives of soy molasses such as an isoflavone glucoside enriched soy molasses material and an aglucone isoflavone enriched soy molasses material. Accordingly, these terms are used interchangeably herein. [0027]
  • An isoflavone enriched material may be recovered from the condensed soy molasses material. The condensed soy molasses material may be diluted with water to a solids content of from about 6% to about 13%, with 13% being most preferred. Dilution of the condensed soy molasses material is not a requirement for the process, however, diluting the relatively thick condensed soy molasses material facilitates processing the material. [0028]
  • The condensed soy molasses material, preferably diluted, is treated at a pH and a temperature at which a majority of the isoflavones will separate from the liquid fraction of the condensed soy molasses upon performing a separation procedure. In a preferred embodiment, the condensed soy molasses material is treated at a pH of about 3.0 to about 6.5 and a temperature of about 0° C. to about 35° C. to maximize the insolubility of the isoflavones in the liquid fraction of the condensed soy molasses. Isoflavones may be separated from the liquid fraction of the condensed soy molasses at pH values outside the preferred range and at temperatures above 35° C., however, these conditions are less preferred since less isoflavones are separated in the separation procedure. The pH of the condensed soy molasses may be adjusted with a suitable conventional acidic or basic reagent, if necessary. It is most preferred that the pH of the condensed soy molasses be adjusted to about 4.5. It is also preferred to chill or cool the condensed soy molasses to a temperature of about 0° C. to about 10° C., and most preferably to a temperature of about 4° C. to about 7° C. [0029]
  • The condensed soy molasses material is then subjected to a separation procedure to separate a cake of isoflavone enriched material from the liquid fraction of the condensed soy molasses material. The separation is performed while the soy molasses material is maintained under the previously described pH and temperature conditions. [0030]
  • In one embodiment, the cake of isoflavone enriched material is separated by centrifuging the soy molasses material and decanting the supernatant from the cake. Centrifugation is preferably performed at about 3,000 to about 10,000 rpm for approximately 30 minutes at about 0° C. to about 10° C. [0031]
  • In another embodiment, the isoflavone enriched cake may be separated from the soy molasses material by filtration. Preferably the filtration is done at the previously described pH and temperature conditions, most preferably at a pH of about 4.5 and a temperature of about 0° C. to about 10° C. [0032]
  • The separated cake of isoflavone enriched material contains a significant amount of isoflavones therein. Preferably the cake of isoflavone enriched material contains at least 20 mg of isoflavones per gram of cake material, on a dry basis (at least about 2% isoflavones by weight) and more preferably contains from about 20 mg to about 50 mg of isoflavones per gram of cake material (from about 2% to about 5% isoflavones, by weight). [0033]
  • In another aspect of the present invention, a cake of isoflavone glucoside enriched material may be recovered from soy molasses. A soy molasses material is obtained as described above. Although not a requirement, it is preferred that the soy molasses material be a condensed soy molasses material diluted to a solids content of from about 6% to about 13%, and most preferably about 13%, to facilitate processing the material. [0034]
  • A conversion operation is then performed on the soy molasses material to convert isoflavone conjugates in the soy molasses material to isoflavone glucosides. A substantial portion of the isoflavones in the soy molasses material are isoflavone conjugates, therefore the conversion substantially increases the amount of isoflavone glucosides in the soy molasses material. The conversion has been found to be dependent on the pH and the temperature of the soy molasses material. [0035]
  • The pH range for conversion of the isoflavone conjugates to isoflavone glucosides in a soy molasses material is from about 6 to about 13.5. The pH of the soy molasses should be adjusted to the desired pH, if necessary, with a suitable base, caustic agent, or basic reagent if the pH is to be raised, or, if the pH is to be lowered, with a suitable acid or acid reagent. The conversion of isoflavone conjugates to isoflavone glucosides has been found to be base catalyzed, and so it is most preferred to utilize a high pH to achieve rapid conversion. The most preferred pH for conversion of the isoflavone conjugates to isoflavone glucosides is a pH of about 9 to about 11. [0036]
  • The temperature range for conversion of the isoflavone conjugates to isoflavone glucosides in soy molasses is from about 2° C. to about 120° C. The temperature range at which the conversion readily occurs depends on the pH of the soy molasses material. The inventors have found that the conversion occurs easily at lower temperatures when the pH is relatively high. For example, at a pH of about 11 the conversion occurs rapidly and efficiently at a temperature range of about 5° C. to about 50° C. At a pH of about 9 conversion occurs efficiently within a temperature range of about 45° C. to about 75° C. When the pH of the soy molasses material is relatively low, the conversion occurs at higher temperatures. For example, at a pH of about 6, the conversion occurs within a temperature range of about 80° C. to about 120° C. In a preferred embodiment, the conversion is effected at about 35° C. and a pH of about 11. In another preferred embodiment, the conversion is effected at a temperature of about 73° C. and a pH of about 9. [0037]
  • The time period required for conversion of isoflavone conjugates to isoflavone glucosides depends primarily upon the pH and temperature range utilized in the soy molasses material. Such conversion times typically range from about 15 minutes up to several hours or longer. Conversion occurs more rapidly at a higher pH and at a higher temperature. At a pH of about 9, conversion is substantially complete in about 4 hours to about 6 hours at 73° C. In a most preferred embodiment, the isoflavone conjugates are converted to isoflavone glucosides in about 30 minutes to about 1 hour, preferably about 45 minutes, at a pH of about 11 and at a temperature of about 35° C. [0038]
  • The conversion of the isoflavone conjugates to isoflavone glucosides is remarkably efficient, converting at least a majority, and preferably substantially all of the isoflavone conjugates present to isoflavone glucosides. The term a “majority” refers to an extent of conversion of at least about 50%. The term “substantially all” refers to an extent of conversion of at least about 80%, and most preferably at least about 90%. [0039]
  • Following the conversion of the isoflavone conjugates to isoflavone glucosides, a cake of isoflavone glucoside enriched material may be separated from the soy molasses material. The soy molasses is condensed by conventional means, if the soy molasses material is not already condensed. The condensed soy molasses material is treated at a pH and a temperature at which a majority of the isoflavone glucosides will separate from the liquid fraction of the condensed soy molasses material in a separation procedure. In a preferred embodiment the condensed soy molasses material is maintained at a pH of about 3 to about 6.5, most preferably about 4.5, and at a temperature of about 0° C. to about 35° C., preferably about 0° C. to about 10° C., and most preferably about 4° C. to about 7° C., during the separation process. The pH of the condensed soy molasses material may be adjusted with a suitable conventional acidic or basic reagent, if necessary. [0040]
  • The separation may be effected by conventional means for separating solids from a liquid. The isoflavone glucoside enriched cake is preferably separated by centrifugation or filtration as described above with respect to separating an isoflavone enriched cake from the liquid fraction of a condensed soy molasses material. [0041]
  • The separated cake of isoflavone glucoside enriched material contains a significant amount of isoflavone glucosides therein. Preferably the cake of isoflavone glucoside enriched material contains at least 20 mg of isoflavone glucosides per gram of cake material, on a dry basis (at least about 2% isoflavone glucosides by weight) and more preferably contains from about 20 mg to about 50 mg of isoflavone glucosides per gram of cake material (from about 2% to about 5% isoflavone glucosides, by weight). [0042]
  • In yet another aspect of the invention, a cake of aglucone isoflavone enriched material may be recovered from soy molasses. A soy molasses material is obtained as described above, preferably a condensed soy molasses material diluted with water to a solids content of about 6% to about 13%. The soy molasses material is treated to convert the isoflavone conjugates to isoflavone glucosides as described above. [0043]
  • An enzymatic conversion operation is then performed on the isoflavone glucoside enriched soy molasses material by contacting a suitable enzyme with isoflavone glucosides in the soy molasses material at a suitable pH and temperature to convert the isoflavone glucosides to aglucone isoflavones. The two-step conversion process effectively converts substantially all of the isoflavone conjugates and isoflavone glucosides in the soy molasses material to aglucone isoflavones, substantially increasing the amount of aglucone isoflavones in the soy molasses material. [0044]
  • The conversion of isoflavone glucosides to aglucone isoflavones has been found to be dependent on a variety of factors including the type of enzymes present in the soy molasses material, distribution of enzyme concentrations, activities of the enzymes, and the pH and temperature of the soy molasses material during the conversion. The enzymes required to effect the conversion are enzymes capable of cleaving the glucosidic linkage between the isoflavone moiety and the glucose molecule of the isoflavone glucosides. In a preferred embodiment, the enzymes are saccharidase or gluco-amylase enzymes capable of cleaving 1,4-glucoside bonds. The enzymes may be inherently present in the soy molasses material, or may be commercially available enzymes which are added to the soy molasses material. Inherently present enzymes are referred to herein as “residual” enzymes, and enzymes that are added to the soy molasses material are referred to herein as “supplemental” enzymes. [0045]
  • Sufficient enzyme should be present in the soy molasses material to convert at least a majority, and preferably substantially all, of the isoflavone glucosides to aglucone isoflavones. Generally, if the residual enzymes in the soy molasses material are insufficient to effect the conversion, supplemental enzymes should be added to the soy molasses material. In a preferred embodiment, supplemental enzymes are added to the soy molasses material regardless of whether sufficient residual enzymes are present in the soy molasses material since addition of supplemental enzymes dramatically decreases the time necessary to effect substantially complete conversion of the glucosides to aglucones. If supplemental enzymes are added, the supplemental enzymes should be added so that the total concentration of enzyme present is about 0.1% to about 10% by weight of the solids in the soy molasses material on a dry basis. [0046]
  • Supplemental enzymes are selected based on optimum activity at selected pH and temperature conditions, and cost effectiveness. The supplemental enzymes are enzymes capable of cleaving the bond between the isoflavone moiety and the glucose molecule of the isoflavone glucosides, such as saccharidase and gluco-amylase enzymes capable of cleaving 1,4-glucoside bonds. Preferred supplemental enzymes are commercially available alpha-and beta-glucosidase enzymes, beta-galactosidase enzymes, gluco-amylase enzymes, and pectinase enzymes. Particularly preferred are enzymes such as Biopectinase 100L (which is preferably utilized at a pH range of from about 3 to about 6), Biopectinase 300L (optimum pH range from about 3 to about 6), Biopectinase OK 70L (optimum pH range from about 3 to about 6), Biolactase 30,000 (optimum pH range from about 3 to about 6) Neutral Lactase (optimum pH range from about 6 to about 8), all of which are available from Quest International, 1833 57th Street, Post Office Box 3917, Sarasota, Fla. 34243. Also especially preferred are Lactase F (which is preferably utilized at a pH range of from about 4 to about 6), and Lactase 50,000 (optimum pH range from about 4 to about 6), both available from Amano International Enzyme Co., Inc., Post Office Box 1000, Troy, Va. 22974. Other particularly preferred supplemental enzymes include G-Zyme G990 (optimum pH from about 4 to about 6) and Enzeco Fungal Lactase Concentrate (optimum pH from about 4 to about 6) available from Enzyme Development Corporation, 2 Penn Plaza, Suite 2439, New York, N.Y. 10121; Lactozyme 3000L (which preferably is utilized at a pH range from about 6 to about 8), and Alpha-Gal 600L (which preferably is utilized at a pH range of from about 4 to about 6.5), available from Novo Nordisk Bioindustrials, Inc., 33 Turner Road, Danbury, Conn. 06813; Maxilact L2000 (which is preferably utilized at a pH range of from about 4 to about 6), available from Gist Brocades Food Ingredients, Inc., King of Prussia, Pa., 19406; and Neutral Lactase (which is preferably utilized at a pH range of from about 6 to about 8), available from Pfizer Food Science Group, 205 East 42nd Street, New York, N.Y. 10017. [0047]
  • The pH range for conversion of the isoflavone glucosides to aglucone isoflavones is from about 3 to about 9. The pH that is utilized depends primarily upon the type of enzyme used, and should be selected accordingly. The residual enzyme is active within a pH range of about 7 to about 9, although it is believed that the pH of the soy molasses material is lowered during the course of the conversion. The supplemental enzymes are active within an optimum pH range specified by the manufacturer of the enzyme, as shown above for several specific enzymes. Typically the supplemental enzymes are active either in a neutral pH range from about 6 to about 8, or in an acidic pH range from about 3 to about 6. [0048]
  • The pH of the soy molasses material may be adjusted to a desired value for conducting the conversion of isoflavone glucosides to aglucone isoflavones. In most instances the pH is reduced from the relatively high or basic pH required to convert the isoflavone conjugates to isoflavone glucosides by the addition of one or more suitable acids such as acetic acid, sulfuric acid, phosphoric acid, hydrochloric acid, or any other suitable reagent. [0049]
  • The temperature range of the soy molasses material for the conversion of glucosides to aglucones is from about 5° C. to about 75° C. The temperature significantly affects the activity of the enzymes, and therefore, the rate of conversion. The supplemental enzymes may be active above 70° C., for example Alpha-Gal 600L is active at 75° C., however, it is preferred to conduct the conversion at lower temperatures to avoid enzyme deactivation. In a preferred embodiment, the conversion is effected between about 35° C. and about 45° C. [0050]
  • The time required for conversion of the glucosides to aglucones depends upon enzyme-related factors, particularly concentration, and the temperature and pH of the system. In most instances it is possible to achieve substantially complete conversion within 24 hours, however, it is preferred that supplemental enzyme be added to dramatically increase the rate of the reaction. The selected supplemental enzyme, enzyme concentration, pH and temperature preferably cause substantially complete conversion within about 2 hours, and most preferably within about 1 hour. [0051]
  • The conversion of the isoflavone glucosides to aglucone isoflavones is remarkably efficient, converting at least a majority, and preferably substantially all of the glucosides present to aglucones. The term “a majority” refers to an extent of conversion of at least about 50%. The term “substantially all” refers to an extent of conversion of at least about 80%, and most preferably at least about 90%. [0052]
  • Following the conversion of the isoflavone glucosides to aglucone isoflavones the soy molasses material is condensed as described above, if the soy molasses material has not already been condensed. A cake of aglucone isoflavone enriched material may be separated from the liquid fraction of the condensed soy molasses material. The soy molasses material is treated at a pH and a temperature at which a majority of the aglucone isoflavones will separate from the liquid fraction of the condensed soy molasses material in a separation procedure. Preferably, the condensed soy molasses material is maintained at a pH of about 3 to about 6.5, most preferably about 4.5, and at a temperature of about 0° C. to about 35° C., preferably about 0° C. to about 10° C., and most preferably about 4° C. to about 7° C., during the separation process. The pH of the condensed soy molasses material may be adjusted with a suitable conventional acidic or basic reagent, if necessary. [0053]
  • The separation may be effected by conventional means for separating solids from a liquid. The aglucone isoflavone enriched cake is preferably separated by centrifugation or filtration as described above with respect to separating an isoflavone enriched cake from the liquid fraction of a condensed soy molasses material. [0054]
  • The separated cake of aglucone isoflavone enriched material contains a significant amount of aglucone isoflavones therein. Preferably the cake of aglucone isoflavone enriched material contains at least 20 mg of aglucone isoflavones per gram of cake material, on a dry basis (at least about 2% aglucone isoflavones by weight) and more preferably contains from about 20 mg to about 50 mg of aglucone isoflavones per gram of cake material (from about 2% to about 5% aglucone isoflavones, by weight). [0055]
  • An aglucone isoflavone enriched material may also be produced from an isoflavone enriched material recovered from soy molasses, where the process for recovering an isoflavone enriched material from soy molasses is described above. Water is added to the recovered cake of isoflavone enriched material to form a slurry of the isoflavone enriched material. Preferably the slurry is diluted to about 6% to about 13% solids, although a higher solids content may be used. Isoflavone conjugates in the slurry are then converted to isoflavone glucosides by treating the slurry under the same conditions described above with respect to converting isoflavone conjugates to isoflavone glucosides in soy molasses. In particular, the slurry is treated at a pH of about 6 to about 13.5, preferably about pH 9 to about pH 11, and a temperature of about 2° C. to about 120° C. for a period of about 15 minutes to several hours. Most preferably the slurry is treated at a pH of about 11 and a temperature of about 5° C. to about 50° C., preferably about 35° C., for a period of about 30 minutes to about 1 hour; or at a pH of about 9 and a temperature of about 45° C. to about 75° C., preferably about 73° C., for a period of about 4 hours to about 6 hours. If desired, an isoflavone glucoside enriched material may be separated from the slurry in a manner similar to the separation of an isoflavone enriched material from soy molasses described above. [0056]
  • Isoflavone glucosides in the slurry are then converted to aglucone isoflavones under the same conditions described above with respect to converting isoflavone glucosides to aglucone isoflavones in a soy molasses material. In particular, the isoflavone glucosides in the slurry are contacted with an enzyme capable of cleaving the glucosidic linkage between the isoflavone moiety and the glucose molecule of the isoflavone glucosides under suitable pH and temperature conditions for a period of time sufficient to convert the isoflavone glucosides to aglucone isoflavones. Preferred enzymes, pH conditions, temperatures, and time periods are described above. An aglucone isoflavone enriched material may be separated from the slurry in a manner similar to the separation of an isoflavone enriched material from soy molasses described above. [0057]
  • An aglucone isoflavone enriched material may also be produced from an isoflavone glucoside enriched material recovered from a soy molasses material, where the process for recovering an isoflavone glucoside enriched material from a soy molasses material is described above. Water is added to the recovered cake of isoflavone glucoside enriched material to form a slurry of the isoflavone glucoside enriched material. Preferably the slurry is diluted to about 6% to about 13% solids, although a higher solids content may be used. The isoflavone glucosides in the slurry are converted to aglucone isoflavones in the same manner described above with respect to the isoflavone glucoside enriched slurry formed from an isoflavone enriched slurry. An aglucone isoflavone enriched material may be separated from the slurry after the conversion in a manner similar to the separation of an isoflavone enriched material from soy molasses described above. [0058]
  • Experimental
  • The present invention is illustrated in more detail by the following examples. The examples are intended to be illustrative, and should not be interpreted as limiting or otherwise restricting the scope of the invention in any way. [0059]
  • As noted above, soy materials, including soy molasses, include the genistein, daidzein, and glycitein “families” of isoflavones having corresponding glucoside, conjugate, and aglucone members, where the genistein family contains the conjugates 6″-OMal genistin, 6″-OAc genistin, the glucoside genistin, and the aglucone genistein; the daidzein family contains the conjugates 6″-OMal daidzin, 6″-OAc daidzin, the glucoside daidzin, and the aglucone daidzein; and the glycitein family includes the conjugate 6″-OMal glycitin, the glucoside glycitin, and the aglucone glycitein. In the following examples the relative concentrations of isoflavones are measured either as a total concentration of an isoflavone family, or as individual percentages of each isoflavone in a family of isoflavones. For example, the total concentration of the genistein family of isoflavones is the sum of the concentrations of 6″-OMal genistin, 6″-OAc genistin, genistin, and genistein, and the percentage of each of the isoflavones in the genistein family is determined relative to the other genistein family isoflavones: % genistin+% 6″OMal genistin+% 6″OAc genistin+% genistein=100%.[0060]
  • EXAMPLE 1
  • In a first experiment, the recovery of an isoflavone enriched material from soy molasses is examined at various concentrations of soy molasses. The total concentration of each isoflavone family is measured in a soy molasses sample having a selected concentration, in a cake separated from the soy molasses sample according to the method of the invention, and in the liquid whey from which the cake is removed by the separation procedure. [0061]
  • Soy molasses is analyzed for the total concentration of all forms of isoflavones present. Samples of the soy molasses are diluted with water to a solids content of 28% (1:2 dilution), 13.7% (1:4 dilution), and 6.6% (1:8 dilution). All samples are pH adjusted to 4.5. The treated samples are then centrifiged at a rate of between 3000 rpm for 30 minutes to separate and produce liquid whey and cake portions from the samples. One set of samples is centrifuged at a temperature of 0.6° C. Samples having 28% and 13.7% soy molasses solids are centrifuged at a temperature of 60° C. for comparison with samples having the same concentration of soy molasses solids that are separated at 0.6° C. The resulting liquid and cake portions of the samples are analyzed for the total concentration of all forms of isoflavones present. [0062]
  • Table 1 sets forth the concentrations of isoflavones in the various cake and liquid fractions obtained from the previously described testing. The indicated totals are the totals of all forms of the particular isoflavone including conjugates, glucoside, and aglucone forms expressed in mg of isoflavone per gram of cake or liquid fraction solids. [0063]
    TABLE 1
    Total Total Total
    Genistein Daidzein Glycitein
    (family) (family) (family)
    Sample mg/g mg/g mg/g
    Soy Molasses 6.1 4.8 1.0
    Starting Material
    Not separated
    1:2 Dilution (28% solids) 2.8 3.0 0.6
    Whey separated at 0.6° C.
    1:2 Dilution 16.9 10.9 1.9
    Cake separated at 0.6° C.
    1:2 Dilution 3.8 4.0 0.8
    Whey separated at 60° C.
    1:2 Dilution 14.1 8.2 1.5
    Cake separated at 60° C.
    1:4 Dilution (13.7% solids) 3.0 3.4 0.7
    Whey separated at 0.6° C.
    1:4 Dilution 18.3 11.0 2.0
    Cake separated at 0.6° C.
    1:4 Dilution 4.4 4.3 0.8
    Whey separated at 60° C.
    1:4 Dilution 13.4 7.2 1.5
    Cake separated at 60° C.
    1:8 Dilution (6.6% solids) 4.3 4.5 0.9
    Whey separated at 0.6° C.
    1:8 Dilution 20.1 10.2 2.1
    Cake separated at 0.6° C.
  • In all separated samples, the concentration of isoflavones is significantly higher in the cake than in soy molasses starting material and much higher than the concentration of isoflavones in the liquid whey fraction solids. The samples separated at 0.6° C. contained a higher concentration of isoflavones in the cake than corresponding samples separated at 60° C., which had higher concentrations of isoflavones in the whey fraction solids. [0064]
  • EXAMPLE 2
  • In another experiment, the recovery of an isoflavone glucoside enriched material from soy molasses is examined. Isoflavone conjugates in the soy molasses are converted to isoflavone glucosides, and an isoflavone glucoside enriched cake is separated from the soy molasses material. The extent of conversion is determined by the quantitative decrease of the percentage and concentration of malonate and acetate esters of an isoflavone family coupled with a corresponding quantitative increase of the percentage of the glucoside of the same isoflavone family. [0065]
  • Soy molasses starting material is analyzed for concentration of individual isoflavone compounds. Two samples of the soy molasses material are made by diluting the soy molasses with water in the following ratios: 1:4(100 g of molasses+300 g water); and 1:8(50 g of molasses+350 g water). The pH of the samples is adjusted to 11, and the temperature of the samples is held at 35° C. for 30 minutes. The pH of the samples is then adjusted to 4.5 and the temperature is adjusted to 4° C. The samples are centrifuged at 10,000 rpm at 4° C. to separate the molasses samples into a cake and a liquid whey. The whey and the cake are analyzed for concentration of individual isoflavone compounds. [0066]
  • Table 2 illustrates the change in the proportions between the various forms of isoflavones resulting from the conversion of isoflavone conjugates to isoflavone glucosides as compared to the soy molasses starting material. Isoflavone concentrations are indicated as parts per million(ppm) within the sample, and as percentages of the total amount of the particular isoflavone (the total of the conjugate, glucoside, and aglucone forms) within the liquid or cake portion. [0067]
    TABLE 2
    6″- 6″- 6″- 6″- 6″-
    OMAL- OAC- OMAL- OAC- OMAL-
    Sample Genistin Genistin Genistin Genistein Daidzin Daidzin Daidzin Daidzein Glycitin Glycitin Glycitein
    Soy Molasses
    ppm 4678 1329 0 88 3533 928 210 84 500 105 360
    % isoflavone 77 22 0 1 74 20 4 2 52 11 37
    1:4 Dilution Whey
    ppm 2221 17 0 30 2652 179 29 21 341 28 0
    % isoflavone 98 1 0 1 92 6 1 1 92 8 0
    1:4 Dilution Cake
    ppm 28621 68 0 261 16133 192 0 232 1442 0 66
    % isoflavone 99 0 0 1 97 1 0 1 96 0 4
    1:8 Dilution Whey
    ppm 2852 24 0 36 3356 187 0 27 406 28 0
    % isoflavone 98 1 0 1 94 5 0 1 94 6 0
    1:8 Dilution Cake
    ppm 27517 101 0 272 12617 138 0 245 1146 0 0
    % isoflavone 99 0 0 1 97 1 0 2 100 0 0
  • In all samples subjected to conditions for conversion of isoflavone conjugates to isoflavone glucosides the percentage of isoflavone glucosides in both cake and liquid portions is significantly higher than in the corresponding unconverted soy molasses sample, and the percentage of corresponding isoflavone conjugates in the samples is significantly lower, demonstrating that a large portion of isoflavone conjugates are converted to their glucoside form. Furthermore, upon separation a large proportion of the glucoside isoflavones are separated in the cake to form an isoflavone glucoside enriched material, as can be seen from the relative concentrations of the soy molasses starting material and the whey and cake portions of each sample. [0068]
  • EXAMPLE 3
  • In another experiment, the conversion of isoflavones to aglucone isoflavones in soy molasses is examined. Isoflavone conjugates in the soy molasses are converted to isoflavone glucosides, and the isoflavone glucosides are then converted to aglucone isoflavones. The extent of conversion of the isoflavone glucosides to aglucone isoflavones is determined by the quantitative decrease of the concentration of the glucoside of an isoflavone family coupled with a corresponding quantitative increase of the percentage of the aglucone of the same isoflavone family. [0069]
  • Soy molasses starting material is diluted 1:4 with water and is analyzed for concentration of individual isoflavone compounds. The pH of the molasses is then adjusted to 11. The soy molasses is held at room temperature for 1 hour to produce a glucoside enriched soy molasses material. The glucoside enriched soy molasses material is analyzed for concentration of individual isoflavone compounds. Four samples are prepared from the glucoside enriched soy molasses material after the pH of the material is adjusted to 4.5. Each sample is inoculated with an enzyme, where the following enzymes are added to the samples, respectively, at 10% by weight of the molasses solids in each sample: G-Zyme 990, Biopectinase 100L, Lactase 50,000, and Alpha-Gal 600L. The samples are then treated at 50° C. for 6 hours to form an aglucone isoflavone enriched soy molasses material. The aglucone isoflavone enriched soy molasses is then analyzed for isoflavone content. [0070]
  • Table 3 illustrates the distribution between the various forms of isoflavones resulting from the previously described testing. Isoflavone concentrations are indicated as parts per million(ppm) within the sample, and as percentages of the total amount of the particular isoflavone (the total of the conjugate, glucoside, and aglucone forms). [0071]
    TABLE 3
    6″- 6″- 6″- 6″- 6″-
    OMAL- OAC- OMAL- OAC- OMAL-
    Sample Genistin Genistin Genistin Genistein Daidzin Daidzin Daidzin Daidzein Glycitin Glycitin Glycitein
    Soy Molasses
    ppm 4678 1329 0 88 3533 928 210 84 500 105 360
    % isoflavone 77 22 0 1 74 20 4 2 52 11 37
    Glucoside rich
    soy molasses
    ppm 6763 0 0 104 4377 0 0 43 433 0 0
    % isoflavone 98 0 0 2 99 0 0 1 100 0 0
    G-Zyme 990, 10%
    ppm 3903 0 0 1993 840 0 82 2331 346 0 114
    % isoflavone 66 0 0 44 27 0 2 71 75 0 25
    Biopectinase
    100 L, 10%
    ppm 2865 0 0 2919 541 0 94 2701 195 0 237
    % isoflavone 50 0 0 50 16 3 81 45 0 55
    Lactase 50,000,
    10%
    ppm 0 0 0 4601 0 0 92 2875 0 0 366
    % isoflavone 0 0 0 100 0 0 3 97 0 0 100
    Alpha-Gal 600 L,
    10%
    ppm 28 0 0 4566 0 0 89 2882 0 0 356
    % isoflavone 1 0 0 99 0 0 3 97 0 0 100
  • The aglucone isoflavone content of the enzymatically treated samples is significantly higher than the soy molasses and the glucoside enriched soy molasses material, indicating that the enzymatic treatment converted substantial amounts of glucoside isoflavones to aglucone isoflavones. Selection of the proper enzyme, enzyme concentration, pH and temperature for the conversion permits conversion of substantially all of the isoflavone glucosides to aglucone isoflavones, as demonstrated by the isoflavone distribution in the Lactase 50,000 and Alpha-Gal 600L samples. [0072]
  • EXAMPLE 4
  • In a final experiment, the isoflavone content of an isoflavone enriched material, an isoflavone glucoside enriched material, and an aglucone isoflavone enriched material is examined and the distribution of the isoflavones in the materials is compared. Soy molasses is diluted to a 1:4 ratio with water. A sample of the diluted soy molasses is adjusted to a pH of 4.5, is chilled to a temperature of 0.6° C. in an ice bath for 30 minutes, and is centrifuged at a rate of 3000 rpm for 30 minutes to separate a cake of isoflavone enriched material. The remaining diluted soy molasses is then adjusted to a pH of 11 with sodium hydroxide and is treated at 50° C. for 1 hour to convert isoflavone conjugates in the molasses to isoflavone glucosides. A sample of the glucoside enriched molasses is adjusted to a pH of 4.5, is chilled to a temperature of 0.6° C. in an icebath for 30 minutes, and is centrifuged at a rate of 3000 rpm for 30 minutes to separate a cake of isoflavone glucoside enriched material. The remaining isoflavone glucoside enriched soy molasses material is adjusted to pH 4.5, and the enzyme G-Zyme 990 is added to the material at a concentration of 2.6 g enzyme/100 g of molasses material. The enzyme and the isoflavone glucoside enriched soy molasses material are then treated at 50° C. for 18 to 20 hours to convert the isoflavone glucosides to aglucone isoflavones. A sample of the aglucone isoflavone enriched soy molasses material is chilled to a temperature of 0.6° C. in an icebath for 30 minutes, and is centrifuged at a rate of 3000 rpm for 30 minutes to separate a cake of aglucone isoflavone enriched material. The recovered cakes of isoflavone enriched material, isoflavone glucoside enriched material, and aglucone isoflavone enriched material are then analyzed for isoflavone content. [0073]
  • Table 4 below shows the distribution of the isoflavones in the cakes of isoflavone enriched material, isoflavone glucoside enriched material, and aglucone isoflavone enriched material. Isoflavone distribution is indicated as percentages of the total amount of the particular isoflavone (the total of the conjugate, glucoside, and aglucone forms). [0074]
    TABLE 4
    6″- 6″- 6″- 6″- 6″-
    OMAL- OAC- OMAL- OAC- OMAL-
    Sample Genistin Genistin Genistin Genistein Daidzin Daidzin Daidzin Daidzein Glycitin Glycitin Glycitein
    Isoflavone rich
    material
    % isoflavone 83 16 0 1 81 12 5 1 40 8 52
    Glucoside rich
    material
    % isoflavone 99 0 0 1 99 0 0 1 95 0 5
    Aglucone rich
    material
    % isoflavone 3 0 0 97 0 0 0 100 54 18 28
  • The effectiveness of the conversion steps can be seen in the isoflavone distribution of the materials. The isoflavone glucoside enriched material contains significantly higher amounts of isoflavone glucosides than the isoflavone enriched material and the aglucone isoflavone material, having an isoflavone content which is comprised of almost entirely isoflavone glucosides. The aglucone isoflavone enriched material contains significantly higher amounts of aglucone isoflavones than the isoflavone glucoside enriched material and the isoflavone enriched material, having an isoflavone content which is comprised of almost entirely aglucone isoflavones. [0075]
  • In the above examples, all percentages indicated for 6″-OMal-genistin, 6″-OAc-genistin, 6″-OMal-daidzin, 6″-OAc-daidzin, glycitin, 6″-OMal-glycitin, and glycitein are calculated values. The following is a description of a method for quantifying isoflavones in soy products. The isoflavones are extracted from soy products by mixing 0.75 gram of sample (spray dried or finely ground powder) with 50 ml of 80/20 methanol/water solvent. The mixture is shaken for 2 hours at room temperature with an orbital shaker. After 2 hours, the remaining undissolved materials are removed by filtration through Whatman No. 42 filter paper. Five ml of the filtrate are diluted with 4 ml of water and 1 ml of methanol. [0076]
  • The extracted isoflavones are separated by HPLC (High Performance Liquid Chromatography)using a Hewlett Packard C18 Hypersil reverse phase column. The isoflavones are injected onto the column and eluted with a solvent gradient starting with 88% methanol, 10% water, and 2% glacial acetic acid and ending with 98% methanol and 2% glacial acetic acid. At a flow rate of 0.4 ml/min, all the isoflavones-genistin, 6″-0-acetylgenistin, 6″-0-malonylgenistin, genistein, daidzin, 6″-0-acetyldaidzin, 6″-0-malonyldaidzin, daidzin, glycitin and its derivatives and glycitein—are clearly resolved. Peak detection is by UV absorbence at 260 mm. Identification of the peaks was performed by HPLC-mass spectrometer. [0077]
  • Quantification is achieved by using pure standards (genistin, genistein, daidzin and daidzein) obtained from Indofine Chemical Company, Sommerville, N.J. Response factors (integrated area/concentration) are calculated for each of the above compounds and are used to quantitate unknown samples. For the conjugated forms for which no pure standards are available, response factors are assumed to be that of the parent molecule but corrected for molecular weight difference. The response factor for glycitin is assumed to be that for genistin corrected for molecular weight difference. This method provides the quantities of each individual isoflavone. For convenience, total genistein, total daidzein and total glycitein can be calculated, and represent the aggregate weight of these compounds if all the conjugated forms are converted to their respective unconjugated forms. These totals can also be measured directly by a method using acid hydrolysis to convert the conjugated forms. [0078]
  • The foregoing are merely preferred embodiments of the invention. Various changes and alterations can be made without departing from the spirit and broader aspects thereof as set forth in the appended claims, which are to be interpreted in accordance with the principals of patent law including the Doctrine of Equivalents. [0079]

Claims (82)

What is claimed is:
1. A health supplement comprising a solid material derived from a soy molasses material, wherein said solid material contains at least two isoflavones.
2. The health supplement of claim 1 wherein at least one of said isoflavones is an aglucone isoflavone.
3. The health supplement of claim 2 wherein said aglucone isoflavone is genistein.
4. The health supplement of claim 2 wherein said aglucone isoflavone is daidzein.
5. The health supplement of claim 2 wherein said aglucone isoflavone is glycitein.
6. The health supplement of claim 2 wherein at least two of said isoflavones are aglucone isoflavones.
7. The health supplement of claim 6 wherein said aglucone isoflavones are genistein and daidzein.
8. The health supplement of claim 6 wherein said aglucone isoflavones are genistein and glycitein.
9. The health supplement of claim 6 wherein said aglucone isoflavones are daidzein and glycitein.
10. The health supplement of claim 2 containing genistein, daidzein, and glycitein.
11. The health supplement of claim 1 wherein at least one of said isoflavones is an isoflavone glucoside.
12. The health supplement of claim 11 wherein said isoflavone glucoside is genistin.
13. The health supplement of claim 11 wherein said isoflavone glucoside is daidzin.
14. The health supplement of claim 11 wherein said isoflavone glucoside is glycitin.
15. The health supplement of claim 11 wherein at least two of said isoflavones are isoflavone glucosides.
16. The health supplement of claim 15 wherein said isoflavone glucosides are genistin and daidzin.
17. The health supplement of claim 16 wherein said isoflavone glucosides are genistin and glycitin.
18. The health supplement of claim 16 wherein said isoflavone glucosides are daidzin and glycitin.
19. The health supplement of claim 16 containing genistin, daidzin, and glycitin.
20. The health supplement of claim 1 wherein at least one of said isoflavones is an isoflavone glucoside conjugate.
21. The health supplement of claim 20 wherein said isoflavone glucoside conjugate is 6″-O-acetyl genistin.
22. The health supplement of claim 20 wherein said isoflavone glucoside conjugate is 6″-O-malonyl genistin.
23. The health supplement of claim 20 wherein said isoflavone glucoside conjugate is 6″-O-acetyl daidzin.
24. The health supplement of claim 20 wherein said isoflavone glucoside conjugate is 6″-O-malonyl daidzin.
25. The health supplement of claim 20 wherein said isoflavone glucoside conjugate is 6″-O-malonyl glycitin.
26. The health supplement of claim 1 wherein at least one of said isoflavones is an aglucone isoflavone and at least one of said isoflavones is an isoflavone glucoside.
27. The health supplement of claim 26 wherein said aglucone isoflavone is genistein.
28. The health supplement of claim 27 wherein said isoflavone glucoside is genistin.
29. The health supplement of claim 27 wherein said isoflavone glucoside is daidzin.
30. The health supplement of claim 27 wherein said isoflavone glucoside is glycitin.
31. The health supplement of claim 27 containing at least two isoflavone glucosides.
32. The health supplement of claim 31 wherein said isoflavone glucosides are genistin and daidzin.
33. The health supplement of claim 31 wherein said isoflavone glucosides are genistin and glycitin.
34. The health supplement of claim 31 wherein said isoflavone glucosides are daidzin and glycitin.
35. The health supplement of claim 31 containing genistin, daidzin, and glycitin.
36. The health supplement of claim 26 wherein said aglucone isoflavone is daidzein.
37. The health supplement of claim 36 wherein said isoflavone glucoside is genistin.
38. The health supplement of claim 36 wherein said isoflavone glucoside is daidzin.
39. The health supplement of claim 36 wherein said isoflavone glucoside is glycitin.
40. The health supplement of claim 36 containing at least two isoflavone glucosides.
41. The health supplement of claim 40 wherein said isoflavone glucosides are genistin and daidzin.
42. The health supplement of claim 40 wherein said isoflavone glucosides are genistin and glycitin.
43. The health supplement of claim 40 wherein said isoflavone glucosides are daidzin and glycitin.
44. The health supplement of claim 40 containing genistin, daidzin, and glycitin.
45. The health supplement of claim 26 wherein said aglucone isoflavone is glycitein.
46. The health supplement of claim 46 wherein said isoflavone glucoside is genistin.
47. The health supplement of claim 46 wherein said isoflavone glucoside is daidzin.
48. The health supplement of claim 46 wherein said isoflavone glucoside is glycitin.
49. The health supplement of claim 46 containing at least two isoflavone glucosides.
50. The health supplement of claim 49 wherein said isoflavone glucosides are genistin and daidzin.
51. The health supplement of claim 49 wherein said isoflavone glucosides are genistin and glycitin.
52. The health supplement of claim 49 wherein said isoflavone glucosides are daidzin and glycitin.
53. The health supplement of claim 49 containing genistin, daidzin, and glycitin.
54. The health supplement of claim 26 containing at least two aglucone isoflavones
55. The health supplement of claim 54 wherein said aglucone isoflavones are genistein and daidzein.
56. The health supplement of claim 55 wherein said isoflavone glucoside is genistin.
57. The health supplement of claim 55 wherein said isoflavone glucoside is daidzin.
58. The health supplement of claim 55 wherein said isoflavone glucoside is glycitin.
59. The health supplement of claim 55 containing at least two isoflavone glucosides.
60. The health supplement of claim 59 wherein said isoflavone glucosides are genistin and daidzin.
61. The health supplement of claim 59 wherein said isoflavone glucosides are genistin and glycitin.
62. The health supplement of claim 59 wherein said isoflavone glucosides are daidzin and glycitin.
63. The health supplement of claim 59 containing genistin, daidzin, and glycitin.
64. The health supplement of claim 54 wherein said aglucone isoflavones are genistein and glycitein.
65. The health supplement of claim 64 wherein said isoflavone glucoside is genistin.
66. The health supplement of claim 64 wherein said isoflavone glucoside is daidzin.
67. The health supplement of claim 64 wherein said isoflavone glucoside is glycitin.
68. The health supplement of claim 64 containing at least two isoflavone glucosides.
69. The health supplement of claim 68 wherein said isoflavone glucosides are genistin and daidzin.
70. The health supplement of claim 68 wherein said isoflavone glucosides are genistin and glycitin.
71. The health supplement of claim 68 wherein said isoflavone glucosides are daidzin and glycitin.
72. The health supplement of claim 68 containing genistin, daidzin, and glycitin.
73. The health supplement of claim 54 wherein said aglucone isoflavones are daidzein and glycitein.
74. The health supplement of claim 73 wherein said isoflavone glucoside is genistin.
75. The health supplement of claim 73 wherein said isoflavone glucoside is daidzin.
76. The health supplement of claim 73 wherein said isoflavone glucoside is glycitin.
77. The health supplement of claim 73 containing at least two isoflavone glucosides.
78. The health supplement of claim 77 wherein said isoflavone glucosides are genistin and daidzin.
79. The health supplement of claim 77 wherein said isoflavone glucosides are genistin and glycitin.
80. The health supplement of claim 77 wherein said isoflavone glucosides are daidzin and glycitin.
81. The health supplement of claim 77 containing genistin, daidzin, and glycitin.
82. The health supplement of claim 1 containing genistein, daidzein, glycitein, genistin, daidzin, and glycitin.
US10/283,671 1996-06-11 2002-10-30 Recovery of isoflavones from soy molasses Abandoned US20030119759A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/283,671 US20030119759A1 (en) 1996-06-11 2002-10-30 Recovery of isoflavones from soy molasses

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/661,845 US5821361A (en) 1996-06-11 1996-06-11 Recovery of isoflavones from soy molasses
US09/086,658 US5919921A (en) 1996-06-11 1998-05-29 Recovery of isoflavones from soy molasses
US09/204,808 US6323018B1 (en) 1996-06-11 1998-12-03 Recovery of isoflavones from soy molasses
US10/016,461 US6495141B2 (en) 1996-06-11 2001-10-19 Recovery of isoflavones from soy molasses
US10/283,671 US20030119759A1 (en) 1996-06-11 2002-10-30 Recovery of isoflavones from soy molasses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/016,461 Division US6495141B2 (en) 1996-06-11 2001-10-19 Recovery of isoflavones from soy molasses

Publications (1)

Publication Number Publication Date
US20030119759A1 true US20030119759A1 (en) 2003-06-26

Family

ID=24655352

Family Applications (9)

Application Number Title Priority Date Filing Date
US08/661,845 Expired - Fee Related US5821361A (en) 1996-06-11 1996-06-11 Recovery of isoflavones from soy molasses
US09/086,658 Expired - Fee Related US5919921A (en) 1996-06-11 1998-05-29 Recovery of isoflavones from soy molasses
US09/204,808 Expired - Lifetime US6323018B1 (en) 1996-06-11 1998-12-03 Recovery of isoflavones from soy molasses
US09/204,431 Expired - Lifetime US5990291A (en) 1996-06-11 1998-12-03 Recovery of isoflavones from soy molasses
US10/016,461 Expired - Lifetime US6495141B2 (en) 1996-06-11 2001-10-19 Recovery of isoflavones from soy molasses
US10/283,671 Abandoned US20030119759A1 (en) 1996-06-11 2002-10-30 Recovery of isoflavones from soy molasses
US10/318,154 Expired - Lifetime US6706292B2 (en) 1996-06-11 2002-12-12 Recovery of isoflavones from soy molasses
US10/319,730 Expired - Lifetime US6664382B2 (en) 1996-06-11 2002-12-13 Recovery of isoflavones from soy molasses
US10/320,792 Expired - Lifetime US6680381B1 (en) 1996-06-11 2002-12-16 Recovery of isoflavones from soy molasses

Family Applications Before (5)

Application Number Title Priority Date Filing Date
US08/661,845 Expired - Fee Related US5821361A (en) 1996-06-11 1996-06-11 Recovery of isoflavones from soy molasses
US09/086,658 Expired - Fee Related US5919921A (en) 1996-06-11 1998-05-29 Recovery of isoflavones from soy molasses
US09/204,808 Expired - Lifetime US6323018B1 (en) 1996-06-11 1998-12-03 Recovery of isoflavones from soy molasses
US09/204,431 Expired - Lifetime US5990291A (en) 1996-06-11 1998-12-03 Recovery of isoflavones from soy molasses
US10/016,461 Expired - Lifetime US6495141B2 (en) 1996-06-11 2001-10-19 Recovery of isoflavones from soy molasses

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/318,154 Expired - Lifetime US6706292B2 (en) 1996-06-11 2002-12-12 Recovery of isoflavones from soy molasses
US10/319,730 Expired - Lifetime US6664382B2 (en) 1996-06-11 2002-12-13 Recovery of isoflavones from soy molasses
US10/320,792 Expired - Lifetime US6680381B1 (en) 1996-06-11 2002-12-16 Recovery of isoflavones from soy molasses

Country Status (14)

Country Link
US (9) US5821361A (en)
EP (3) EP0812837B8 (en)
JP (1) JPH1067770A (en)
KR (1) KR100412117B1 (en)
CN (1) CN1195750C (en)
AT (1) ATE302767T1 (en)
AU (1) AU720462B2 (en)
BR (1) BR9703526A (en)
CA (1) CA2207360C (en)
DE (1) DE69734042T2 (en)
ES (1) ES2247617T3 (en)
MX (1) MX9704375A (en)
RU (1) RU2219785C2 (en)
TW (1) TW474930B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040131747A1 (en) * 2001-06-18 2004-07-08 Porter Michael A Modified oilseed material
US20040219281A1 (en) * 2000-11-21 2004-11-04 Cargill, Incorporated Modified oilseed material

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2136233C (en) 1992-05-19 2004-03-30 Graham Edmund Kelly Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US5821361A (en) 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US6521282B1 (en) 1996-08-09 2003-02-18 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable flour and grit
US6579561B2 (en) 1996-08-09 2003-06-17 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable flour and vegetable grit and process for making the same from a vegetable material containing isoflavone
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US6146668A (en) 1997-04-28 2000-11-14 Novogen, Inc. Preparation of isoflavones from legumes
WO1998050026A1 (en) 1997-05-01 1998-11-12 Novogen Inc Treatment or prevention of menopausal symptoms and osteoporosis
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US6228993B1 (en) 1998-10-12 2001-05-08 Central Soya Company, Inc. Soy isoflavone concentrate process and product
US6369200B2 (en) 1997-10-15 2002-04-09 Central Soya Company, Inc. Soy isoflavone concentrate process and product
US6320028B1 (en) 1997-10-15 2001-11-20 Central Soya Company, Inc. Soy isoflavone concentrate process and product
US6004558A (en) * 1998-02-25 1999-12-21 Novogen, Inc. Methods for treating cancer with legume plant extracts
US6132795A (en) * 1998-03-15 2000-10-17 Protein Technologies International, Inc. Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
AUPP260798A0 (en) 1998-03-26 1998-04-23 Novogen Research Pty Ltd Treatment of medical related conditions with isoflavone containing extracts of clover
US6083553A (en) * 1998-06-05 2000-07-04 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
ES2220102T3 (en) * 1998-07-16 2004-12-01 Aaron Tabor SOY FORMULATIONS AND ITS USE TO IMPROVE HEALTH.
JP2000095792A (en) * 1998-09-21 2000-04-04 Showa Sangyo Co Ltd Acquisition of isoflavone composition comprising genistin
CN1069903C (en) * 1998-09-22 2001-08-22 北京市农林科学院畜牧兽医研究所 Method for extracting isoflavone from soybean
EP1135142A4 (en) 1998-12-02 2002-01-02 Cognis Corp Production of a product enriched in isoflavone values from natural sources
US6544566B1 (en) 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
US7285297B1 (en) 1999-04-23 2007-10-23 Archer-Daniels-Midland Company Method of reducing low density liproprotein cholesterol concentration
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
KR100733056B1 (en) * 1999-12-17 2007-06-27 미츠노리 오노 Water-soluble bean-based extracts
AUPQ504300A0 (en) 2000-01-11 2000-02-03 Biorex Health Limited Extraction of flavonoids
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US6505133B1 (en) * 2000-11-15 2003-01-07 Datex-Ohmeda, Inc. Simultaneous signal attenuation measurements utilizing code division multiplexing
JP2002154970A (en) * 2000-11-15 2002-05-28 We'll Corporation:Kk Antiallergic agent
US6355816B1 (en) * 2000-11-27 2002-03-12 Wiley Organics, Inc. Process for isolating saponins from soybean-derived materials
FR2817866B1 (en) * 2000-12-13 2005-01-07 Theramex METHOD FOR EXTRACTING FLAVONIC MIXTURES AND USE OF MIXTURES THUS OBTAINED IN DERMOCOSMAL, FOOD AND PHARMACY
US20020119208A1 (en) * 2000-12-14 2002-08-29 Daniel Chajuss Soy phytochemical composition
FR2818096B1 (en) * 2000-12-14 2004-05-07 Daniel Chajuss PHYTOCHEMICAL COMPOSITION OF SOYBEANS
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
US6555143B2 (en) 2001-02-28 2003-04-29 Johnson & Johnson Consumer Products, Inc. Legume products
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US7116787B2 (en) * 2001-05-04 2006-10-03 Agere Systems Inc. Perceptual synthesis of auditory scenes
JP4403800B2 (en) * 2001-06-21 2010-01-27 不二製油株式会社 Method for producing soluble isoflavone-containing composition
AUPR602201A0 (en) * 2001-06-29 2001-07-26 Biorex Health Limited Flavonoid concentrates
CN1556699B (en) * 2001-07-24 2010-05-12 嘉吉有限公司 Process for isolating phenolic compounds
WO2003082888A1 (en) * 2002-03-26 2003-10-09 Wiley Organics, Inc. Process for isolating genisting from mixtures of soy isoflavones
US7524526B2 (en) * 2002-04-10 2009-04-28 Archer-Daniels-Midland Company Process for producing high purity isoflavones
EP1359215B1 (en) 2002-04-30 2010-03-10 Societe Des Produits Nestle S.A. Use of a soya cell strains with high isoflavone content
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8668914B2 (en) * 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US20040047927A1 (en) * 2002-09-05 2004-03-11 Yaguang Liu Soybean drug and new method of extracting soybean isoflavone
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
CA2504682A1 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
WO2004043945A1 (en) * 2002-11-12 2004-05-27 Wiley Organics, Inc. Method for purifying and separating soy isoflavones
WO2004045541A2 (en) * 2002-11-15 2004-06-03 Cargill, Incorporated Soluble isoflavone compositions
US7718813B2 (en) * 2003-08-15 2010-05-18 Nature Pure Labs Sw, Inc. Hydrolysis and purification of active plant compounds suitable for topical application
KR100449887B1 (en) * 2003-10-31 2004-09-22 주식회사 렉스진바이오텍 Preparation method of extract of Sophorae Fructus containing isoflavone
WO2005077929A1 (en) * 2004-02-09 2005-08-25 Cargill, Incorporated Phenolic compound purification
WO2005077930A1 (en) * 2004-02-09 2005-08-25 Cargill, Incorporated Phenolic compound purification
EP1740191A4 (en) * 2004-04-28 2008-07-30 Univ Brigham Young Use of equol for treating skin diseases
AU2005239890B2 (en) * 2004-05-10 2011-08-18 Instituto Tecnologico Y De Estudios Superiores De Monterrey (Itesm) Cancer cell growth inhibition by black bean (Phaseolus vulgarisL) extracts
US20070134395A1 (en) * 2005-12-13 2007-06-14 Hodges Everett L Method of reducing manganese in defatted soy isolate
US20070141121A1 (en) * 2005-12-20 2007-06-21 Calton Gary J Method of treating kidney disease
US20080044861A1 (en) * 2006-08-15 2008-02-21 Fermalogic, Inc. Methods for Recovering Isoflavones from Fermentation Processes
EP3123863A1 (en) * 2007-01-09 2017-02-01 Novozymes Biologicals Holding A/S Compositions comprising lipo-chitooligosaccharides and flavonoids for enhanced plant growth and yield
PL2215481T5 (en) * 2007-11-15 2017-10-31 Bioporto Diagnostics As Diagnostic use of individual molecular forms of a biomarker
US20090176871A1 (en) * 2008-01-07 2009-07-09 Schoenwetter Phillip E Treatments for Domestic Animals Having Sex Hormone Deficiencies Using Soy Germ Isoflavones
US20100041778A1 (en) * 2008-08-14 2010-02-18 Composite Technology Development, Inc. Reconfigurable polymeric foam structure
US20100068346A1 (en) * 2008-09-16 2010-03-18 Hodges Everett L Infant formula
EP2690959B1 (en) 2011-03-31 2016-03-23 Novozymes Biologicals, Inc. Competitive and effective bradyrhizobium japonicum strains
FR2974300B1 (en) 2011-04-19 2013-05-10 Inneov Lab USE OF A COMBINATION OF A CAROTENOID, A PHYTOESTROGEN AND VITAMIN C FOR THE PREVENTION AND / OR TREATMENT OF PIGMENT DISORDERS
FR2974296B1 (en) 2011-04-19 2013-05-24 Inneov Lab USE OF A COMBINATION OF A CAROTENOID, A PHYTOESTROGEN AND VITAMIN C AS AN AGENT FOR HYDRATION OF THE SKIN
CN106211857A (en) 2011-09-08 2016-12-14 诺维信生物农业公司 Method for treating seeds and compositions
BR112014006161A2 (en) 2011-09-14 2017-04-04 Novozymes Bioag As packaging, composition, plant seed, and method for enhancing plant growth
CN104066328B (en) 2011-09-23 2016-03-23 诺维信生物农业公司 For strengthening chitosan oligosaccharide and the method for soybeans they grow
WO2013044208A2 (en) 2011-09-23 2013-03-28 Novozymes Biologicals Holdings A/S Chitooligosaccharides and methods for use in enhancing plant growth
CN104105401B (en) 2011-09-23 2017-03-08 诺维信生物农业公司 For strengthening oligochitosan and the method for corn growth
WO2013044214A1 (en) 2011-09-23 2013-03-28 Novozymes Biologicals Holdings A/S Combinations of lipo-chitooligosaccharides and methods for use in enhancing plant growth
CA2859425C (en) 2011-12-16 2020-05-12 Novozymes Bioag A/S Bradyrhizobium strains
WO2014049546A2 (en) 2012-09-27 2014-04-03 Institut National De La Recherche Agronomique Compositions and methods for enhancing plant growth and development
FR2996135A1 (en) 2012-09-28 2014-04-04 Inneov Lab ORAL COMPOSITION FOR ENHANCING SKIN TOLERANCE FOLLOWING TOPICAL ADMINISTRATION OF RETINOID COMPOUND
US9365464B2 (en) 2012-11-16 2016-06-14 Novozymes Bioag A/S Microbial strains, compositions, and methods for increasing available phosphate for plants
ES2857561T3 (en) 2013-03-28 2021-09-29 Novozymes Bioag As Compositions and methods to improve microbial stability
CN103342691B (en) * 2013-07-09 2015-03-11 内蒙古科然生物高新技术有限责任公司 Method and equipment for extracting isoflavone, saponin and oligosaccharide from soy molasses
UA119331C2 (en) 2013-11-08 2019-06-10 Новозімес Біоаґ А/С Compositions and methods for treating pests
WO2015077278A1 (en) 2013-11-20 2015-05-28 Novozymes Bioag A/S Compositions and methods comprising chromobacterium for controlling plant nematode pests and plant insect pests
US20170027167A1 (en) 2014-03-05 2017-02-02 Novozymes Bioag A/S Formulations comprising polymeric xyloglucan as a carrier for agriculturally beneficial agents
CN103965154B (en) * 2014-05-09 2015-10-14 荆门市德爱生物工程有限公司 A kind of method utilizing soy molasses to produce soybean isoflavones
MX2017000890A (en) 2014-07-23 2017-05-01 Novozymes Bioag As Compositions containing lipo-chitooligosaccharide and microorganism for enhancing plant growth.
CN104805064B (en) * 2015-02-10 2018-03-27 南京林业大学 High temperature resistant flavone aglycone invertase and its application
EP3346842A1 (en) 2015-09-11 2018-07-18 Novozymes BioAG A/S Stable inoculant compositions and methods for producing same
MX2018007932A (en) 2015-12-28 2019-02-26 Novozymes Bioag As Stable inoculant compositions and methods for producing same.
KR102659250B1 (en) 2015-12-28 2024-04-22 노보자임스 바이오아게 에이/에스 Stable inoculant composition and method for producing the same
WO2017210166A1 (en) 2016-05-31 2017-12-07 Novozymes Bioag A/S Stable liquid inoculant compositions and coated plant propagation materials comprising same
BR112018074415A2 (en) 2016-05-31 2019-03-06 Novozymes Bioag As solid non-aqueous inoculant composition, coated plant seed, kit, and method.
EP3558003A1 (en) 2016-12-20 2019-10-30 Novozymes Bioag A/S Stable inoculant compositions and methods for producing same
CA3048997A1 (en) 2017-01-03 2018-07-12 Monsanto Technology Llc Microbial compositions and methods
EP3565397A4 (en) 2017-01-03 2020-06-24 Monsanto Technology LLC Microbial compositions and methods
US11618879B2 (en) 2017-01-04 2023-04-04 Novozymes Bioag A/S Bacillus isolates and uses thereof
EP3565414A1 (en) 2017-01-05 2019-11-13 Novozymes Bioag A/S Lysinibacillus isolates and uses thereof
US11089776B2 (en) 2017-02-28 2021-08-17 Monsanto Technology Llc Containerized liquid formulations
KR102633312B1 (en) 2017-03-24 2024-02-05 노보자임스 바이오아게 에이/에스 Combination of Yeshenia entomophaga and pesticides or other substances
EP3631019B1 (en) 2017-05-26 2023-10-11 Novozymes BioAG A/S Stable inoculant compositions comprising paraffin oils/waxes
BR112019024738A2 (en) 2017-05-26 2020-06-16 Novozymes Bioag A/S USE OF ONE OR MORE METHYLATED VEGETABLE OILS, LIQUID INOCULATING COMPOSITION, COATED PLANT SEED, KIT, AND, METHOD
WO2018218008A1 (en) 2017-05-26 2018-11-29 Novozymes Bioag A/S Stable liquid inoculant compositions comprising dodecane
EP3644730B1 (en) 2017-06-29 2024-07-10 Monsanto Technology LLC Seed treatment process for large liquid volumes
EP3681290A4 (en) 2017-09-12 2021-06-16 Monsanto Technology LLC Processes for the preparation of treated seeds
CN108220356A (en) * 2017-11-20 2018-06-29 荆门市德爱生物工程股份有限公司 A kind of production method of isoflavone genin
BR112020012971A2 (en) 2018-01-08 2020-11-24 Novozymes Bioag A/S use of an anionic surfactant, a method to solubilize lipo-chito-oligosaccharide molecules in an aqueous solvent, and, aqueous lipo-chito-oligosaccharide solution.
WO2019147660A1 (en) 2018-01-23 2019-08-01 Novozymes Bioag A/S Method of enhancing seed germination under abiotic stress with chitin oligosaccharides
US20210251236A1 (en) 2018-05-07 2021-08-19 Novozymes Bioag A/S Microbacterium isolates and uses thereof
CN108503675A (en) * 2018-07-11 2018-09-07 黑龙江八农垦大学 The method for extraction and purification and application thereof of Soybean Leaves glycitin
CA3110709A1 (en) 2018-09-21 2020-03-26 Novozymes Bioag A/S Pesticidal combinations of yersinia and bacillus
AU2019346388A1 (en) 2018-09-24 2021-03-18 Novonesis Plant Biosolutions A/S Pesticidal combinations of Yersinia and insect viruses
US12073350B2 (en) 2019-04-16 2024-08-27 Kao Corporation Method of predicting soybean yield
JP2020174668A (en) * 2019-04-16 2020-10-29 花王株式会社 Method of predicting soybean yield
JP7244338B2 (en) * 2019-04-16 2023-03-22 花王株式会社 Soybean yield prediction method
JP7513291B2 (en) 2019-06-24 2024-07-09 国立研究開発法人農業・食品産業技術総合研究機構 Erwinia isolates and their uses
EP3701796A1 (en) 2019-08-08 2020-09-02 Bayer AG Active compound combinations
WO2021030400A1 (en) 2019-08-13 2021-02-18 Novozymes Bioag A/S Pesticidal combinations of yersinia and proteases
EP3818829A3 (en) 2019-10-16 2021-07-21 Monsanto Technology LLC Granular nematicide compositions
WO2021086695A1 (en) 2019-10-29 2021-05-06 Novozymes Bioag A/S Microbacterium isolates and uses thereof
WO2021101937A1 (en) 2019-11-20 2021-05-27 Novozymes Bioag A/S Pseudomonas isolates and uses thereof
EP4061969A1 (en) 2019-11-22 2022-09-28 Novozymes Bioag A/S Paenibacillus isolates and uses thereof
WO2022125639A1 (en) 2020-12-08 2022-06-16 Monsanto Technology Llc Modified plant-associated bacteria and methods of their use
WO2022207496A1 (en) 2021-03-30 2022-10-06 Bayer Aktiengesellschaft 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide
BR112023019400A2 (en) 2021-03-30 2023-12-05 Bayer Ag 3-(HETERO)ARYL-5-CHLORODIFLOROMETHYL-1,2,4-OXADIAZOLE AS A FUNGICIDE
WO2023017120A1 (en) 2021-08-13 2023-02-16 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
AU2023263693A1 (en) 2022-05-03 2024-10-31 Bayer Aktiengesellschaft Crystalline forms of (5s)-3-[3-(3-chloro-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-(2-chloro-4-methylbenzyl)-5,6-dihydro-4h-1,2,4-oxadiazine
WO2023213626A1 (en) 2022-05-03 2023-11-09 Bayer Aktiengesellschaft Use of (5s)-3-[3-(3-chloro-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-(2-chloro-4-methylbenzyl)-5,6-dihydro-4h-1,2,4-oxadiazine for controlling unwanted microorganisms
WO2024068518A1 (en) 2022-09-28 2024-04-04 Bayer Aktiengesellschaft 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide
WO2024068517A1 (en) 2022-09-28 2024-04-04 Bayer Aktiengesellschaft 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide
WO2024068520A1 (en) 2022-09-28 2024-04-04 Bayer Aktiengesellschaft 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide
WO2024068519A1 (en) 2022-09-28 2024-04-04 Bayer Aktiengesellschaft 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide
EP4295688A1 (en) 2022-09-28 2023-12-27 Bayer Aktiengesellschaft Active compound combination
WO2024104643A1 (en) 2022-11-17 2024-05-23 Bayer Aktiengesellschaft Use of isotianil for controlling plasmodiophora brassica

Citations (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US64938A (en) * 1867-05-21 Improvement in lathes
US168433A (en) * 1875-10-05 Improvement in smoked-beef shavers
US3391001A (en) * 1965-02-26 1968-07-02 Griffith Laboratories Production of flavorful protein hydrolysate
US3461205A (en) * 1961-04-26 1969-08-12 Spofa Vereinigte Pharma Werke Process of extracting proteins from potatoes
US3870805A (en) * 1970-11-04 1975-03-11 Staley Mfg Co A E Process for preparing texturized protein compositions and the resulting product
US3949085A (en) * 1970-05-27 1976-04-06 Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US3974184A (en) * 1973-08-01 1976-08-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Microbial production of certain isoflavones
US4064277A (en) * 1974-08-12 1977-12-20 Kikkoman Shoyu Co., Ltd. Method for processing soybeans
US4157984A (en) * 1977-06-08 1979-06-12 Z-L Limited Antioxidants, antioxidant compositions and methods of preparing and using same
US4163746A (en) * 1973-07-09 1979-08-07 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Metabolic 5-methyl-isoflavone-derivatives, process for the preparation thereof and compositions containing the same
US4218489A (en) * 1977-06-08 1980-08-19 Z-L Limited Partnership Antioxidants, antioxidant compositions and methods of preparing and using same
US4232122A (en) * 1979-01-17 1980-11-04 Z-L Limited Partnership Antioxidants, antioxidant compositions and methods of preparing and using same
US4259358A (en) * 1974-02-14 1981-03-31 Agricultural Production And Vegetable Products, Ltd. Preparation of food products
US4264509A (en) * 1977-06-08 1981-04-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4366248A (en) * 1979-04-11 1982-12-28 Z-L Limited Partnership Fermentation method of preparing antioxidants
US4366082A (en) * 1979-04-11 1982-12-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4390559A (en) * 1979-04-11 1983-06-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4428876A (en) * 1982-08-19 1984-01-31 Tokiwa Kanpo Pharmaceutical Co., Ltd. Process for isolating saponins and flavonoids from leguminous plants
US4841077A (en) * 1985-11-18 1989-06-20 Yamanouchi Pharmaceutical Co., Ltd. Isoflavone derivatives, and salts thereof, and cancerocidal and immunosuppressive agents containing the same
US4889921A (en) * 1987-04-29 1989-12-26 The University Of Toronto Innovations Foundation Production of rapeseed protein materials
US5141746A (en) * 1989-11-10 1992-08-25 Nestec S.A. Process for obtaining genistin malonate and daidzin malonate
US5320949A (en) * 1993-10-12 1994-06-14 Protein Technologies International, Inc. Process for producing aglucone isoflavone enriched vegetable protein fiber
US5424331A (en) * 1994-06-10 1995-06-13 Bio-Virus Research Incorporated Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
US5506211A (en) * 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts
US5516528A (en) * 1995-01-13 1996-05-14 Wake Forest University Dietary phytoestrogen in estrogen replacement therapy
US5554519A (en) * 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
US5569459A (en) * 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5637562A (en) * 1993-10-12 1997-06-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein concentrate and process for producing
US5637561A (en) * 1993-10-12 1997-06-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein whey, whey protein, and process for producing
US5670632A (en) * 1996-01-18 1997-09-23 Acds Technologies, Ltd. Process for obtaining an isoflavone concentrate from a soybean extract
US5679806A (en) * 1995-02-24 1997-10-21 Hauser, Inc. Process for the isolation and purification of isoflavones
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US5726034A (en) * 1996-09-06 1998-03-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same
US5763389A (en) * 1993-10-12 1998-06-09 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein extract and isolate and process for producing
US5789581A (en) * 1995-04-14 1998-08-04 Kikkoman Corporation Process for obtaining malonyl isoflavone glycosides and obtaining isoflavone glycosides or isoflavone aglycons from malonyl isoflavone glycosides
US5792789A (en) * 1996-04-25 1998-08-11 Adir Et Compagnie Acids and esters of diosmetin
US5804234A (en) * 1996-09-13 1998-09-08 Suh; John D. Plant protein for nutritional products and method of making same
US5821361A (en) * 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US5827682A (en) * 1995-06-07 1998-10-27 Protein Technologies International, Inc. Two-step conversion of vegetable protein isoflavone conjugates to aglucones
US5851792A (en) * 1996-04-03 1998-12-22 Shen; Jerome Aglucone isoflavone enriched vegetable protein whey whey protein material aglucone isoflavone material high genistein content material and high daidzein content material and process for producing the same from a vegetable protein whey
US5994508A (en) * 1998-04-13 1999-11-30 Protein Technologies International, Inc. Isoflavone rich protein isolate and process for producing
US6013771A (en) * 1998-06-09 2000-01-11 Protein Technologies International, Inc. Isoflavone rich protein isolate and process for producing
US6033714A (en) * 1996-03-13 2000-03-07 Archer Daniels Midland Company Process for production of isoflavone fractions from soy
US6083553A (en) * 1998-06-05 2000-07-04 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US6132795A (en) * 1998-03-15 2000-10-17 Protein Technologies International, Inc. Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
US6140469A (en) * 1993-10-12 2000-10-31 Protein Technologies International, Inc. Protein isolate having an increased level of isoflavone compounds and process for producing the same
US6171638B1 (en) * 1996-03-13 2001-01-09 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US6391310B1 (en) * 1996-03-13 2002-05-21 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of neurological symptoms
US6565912B1 (en) * 1996-03-13 2003-05-20 Archer-Daniels-Midland Production of isoflavone enriched fractions from soy protein extracts

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264082A (en) 1979-03-26 1981-04-28 Fouchey Jr Charles J Stair climbing cart
DE3523961A1 (en) * 1985-07-04 1987-01-15 Licentia Gmbh DEVICE FOR TREATING AT LEAST ONE CERAMIC ITEM IN AN ALKALINE HYDROXIDE MELT
JPS62126185A (en) * 1985-11-28 1987-06-08 Tsumura Juntendo Inc Production of isoflavone derivative
JPS62126186A (en) * 1985-11-28 1987-06-08 Tsumura Juntendo Inc Production of isoflavone derivative
JPS63245648A (en) * 1987-04-01 1988-10-12 Ajinomoto Co Inc Production of soybean food material
SU1514765A1 (en) 1987-06-02 1989-10-15 Univ Chernovitskij G Method of producing nutrient medium for growing yeast
JPH0714927B2 (en) * 1988-04-06 1995-02-22 キッコーマン株式会社 Method for producing isoflavone compound
JPH0436242A (en) * 1990-05-30 1992-02-06 Fuji Oil Co Ltd Production of soya saponin
JPH0645634B2 (en) * 1991-02-21 1994-06-15 阿保 定吉 Soy isoflavone glycoside
JPH04283283A (en) * 1991-03-08 1992-10-08 Nippon Synthetic Chem Ind Co Ltd:The Free sealing tape
JPH04283518A (en) * 1991-03-12 1992-10-08 Kikkoman Corp Agent for alleviating periodontosis
JPH05170756A (en) * 1991-12-20 1993-07-09 Kikkoman Corp Production of isoflavone compound
CA2136233C (en) * 1992-05-19 2004-03-30 Graham Edmund Kelly Health supplements containing phyto-oestrogens, analogues or metabolites thereof
JPH06287554A (en) * 1993-04-01 1994-10-11 Aomori Pref Gov Production of oxidation-resistant substance from soybean meal or lees of bean curd
AU3689095A (en) 1994-10-03 1996-04-26 Schouten Industries B.V. Food and health products
JP3383718B2 (en) * 1995-02-15 2003-03-04 ニチモウ株式会社 Method for producing product from soy protein
JPH0923822A (en) 1995-07-14 1997-01-28 Nichimo Co Ltd Peptide product and its production
IL115110A (en) * 1995-08-30 1997-08-14 Chajuss Daniel Soy molasses
ES2220102T3 (en) * 1998-07-16 2004-12-01 Aaron Tabor SOY FORMULATIONS AND ITS USE TO IMPROVE HEALTH.

Patent Citations (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US64938A (en) * 1867-05-21 Improvement in lathes
US168433A (en) * 1875-10-05 Improvement in smoked-beef shavers
US3461205A (en) * 1961-04-26 1969-08-12 Spofa Vereinigte Pharma Werke Process of extracting proteins from potatoes
US3391001A (en) * 1965-02-26 1968-07-02 Griffith Laboratories Production of flavorful protein hydrolysate
US3949085A (en) * 1970-05-27 1976-04-06 Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US3870805A (en) * 1970-11-04 1975-03-11 Staley Mfg Co A E Process for preparing texturized protein compositions and the resulting product
US4163746A (en) * 1973-07-09 1979-08-07 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Metabolic 5-methyl-isoflavone-derivatives, process for the preparation thereof and compositions containing the same
US3974184A (en) * 1973-08-01 1976-08-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Microbial production of certain isoflavones
US4259358A (en) * 1974-02-14 1981-03-31 Agricultural Production And Vegetable Products, Ltd. Preparation of food products
US4064277A (en) * 1974-08-12 1977-12-20 Kikkoman Shoyu Co., Ltd. Method for processing soybeans
US4157984A (en) * 1977-06-08 1979-06-12 Z-L Limited Antioxidants, antioxidant compositions and methods of preparing and using same
US4218489A (en) * 1977-06-08 1980-08-19 Z-L Limited Partnership Antioxidants, antioxidant compositions and methods of preparing and using same
US4264509A (en) * 1977-06-08 1981-04-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4232122A (en) * 1979-01-17 1980-11-04 Z-L Limited Partnership Antioxidants, antioxidant compositions and methods of preparing and using same
US4366248A (en) * 1979-04-11 1982-12-28 Z-L Limited Partnership Fermentation method of preparing antioxidants
US4366082A (en) * 1979-04-11 1982-12-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4390559A (en) * 1979-04-11 1983-06-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4428876A (en) * 1982-08-19 1984-01-31 Tokiwa Kanpo Pharmaceutical Co., Ltd. Process for isolating saponins and flavonoids from leguminous plants
US4841077A (en) * 1985-11-18 1989-06-20 Yamanouchi Pharmaceutical Co., Ltd. Isoflavone derivatives, and salts thereof, and cancerocidal and immunosuppressive agents containing the same
US4960908A (en) * 1985-11-18 1990-10-02 Yamanouchi Pharmaceutical Co., Ltd. Isoflavone derivatives, salts thereof, and oncostatic and immunosuppressive agents
US4889921A (en) * 1987-04-29 1989-12-26 The University Of Toronto Innovations Foundation Production of rapeseed protein materials
US5141746A (en) * 1989-11-10 1992-08-25 Nestec S.A. Process for obtaining genistin malonate and daidzin malonate
US5637561A (en) * 1993-10-12 1997-06-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein whey, whey protein, and process for producing
US5320949A (en) * 1993-10-12 1994-06-14 Protein Technologies International, Inc. Process for producing aglucone isoflavone enriched vegetable protein fiber
US5763389A (en) * 1993-10-12 1998-06-09 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein extract and isolate and process for producing
US5352384A (en) * 1993-10-12 1994-10-04 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein fiber
US6140469A (en) * 1993-10-12 2000-10-31 Protein Technologies International, Inc. Protein isolate having an increased level of isoflavone compounds and process for producing the same
US5637562A (en) * 1993-10-12 1997-06-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein concentrate and process for producing
US5506211A (en) * 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts
US5424331A (en) * 1994-06-10 1995-06-13 Bio-Virus Research Incorporated Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
US5516528A (en) * 1995-01-13 1996-05-14 Wake Forest University Dietary phytoestrogen in estrogen replacement therapy
US5569459A (en) * 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5679806A (en) * 1995-02-24 1997-10-21 Hauser, Inc. Process for the isolation and purification of isoflavones
US5789581A (en) * 1995-04-14 1998-08-04 Kikkoman Corporation Process for obtaining malonyl isoflavone glycosides and obtaining isoflavone glycosides or isoflavone aglycons from malonyl isoflavone glycosides
US5827682A (en) * 1995-06-07 1998-10-27 Protein Technologies International, Inc. Two-step conversion of vegetable protein isoflavone conjugates to aglucones
US5554519A (en) * 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
US5670632A (en) * 1996-01-18 1997-09-23 Acds Technologies, Ltd. Process for obtaining an isoflavone concentrate from a soybean extract
US6509381B2 (en) * 1996-03-13 2003-01-21 Archer Daniels Midland Company Method of preparing and using compositions extracted from vegetable matter for the treatment of neurological conditions
US6033714A (en) * 1996-03-13 2000-03-07 Archer Daniels Midland Company Process for production of isoflavone fractions from soy
US6565912B1 (en) * 1996-03-13 2003-05-20 Archer-Daniels-Midland Production of isoflavone enriched fractions from soy protein extracts
US6518319B1 (en) * 1996-03-13 2003-02-11 Archer Daniels Midland Company Method of preparing and using compositions extracted from vegetable matter for the treatment of female symptoms
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US6171638B1 (en) * 1996-03-13 2001-01-09 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US6900240B2 (en) * 1996-03-13 2005-05-31 Archer-Daniels-Midland Company Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer
US6391309B1 (en) * 1996-03-13 2002-05-21 Archer Daniesl Midland Company Method of preparing and using isoflavones for the treatment of female symptoms
US6399072B1 (en) * 1996-03-13 2002-06-04 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of alcoholism
US6395279B1 (en) * 1996-03-13 2002-05-28 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of cancer
US5792503A (en) * 1996-03-13 1998-08-11 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US6391308B1 (en) * 1996-03-13 2002-05-21 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of blood related illnesses
US6391310B1 (en) * 1996-03-13 2002-05-21 Archer Daniels Midland Company Method of preparing and using isoflavones for the treatment of neurological symptoms
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US5851792A (en) * 1996-04-03 1998-12-22 Shen; Jerome Aglucone isoflavone enriched vegetable protein whey whey protein material aglucone isoflavone material high genistein content material and high daidzein content material and process for producing the same from a vegetable protein whey
US5792789A (en) * 1996-04-25 1998-08-11 Adir Et Compagnie Acids and esters of diosmetin
US5919921A (en) * 1996-06-11 1999-07-06 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US6323018B1 (en) * 1996-06-11 2001-11-27 Protein Technologies Int'l Lnc. Recovery of isoflavones from soy molasses
US5990291A (en) * 1996-06-11 1999-11-23 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US5821361A (en) * 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US5726034A (en) * 1996-09-06 1998-03-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same
US5804234A (en) * 1996-09-13 1998-09-08 Suh; John D. Plant protein for nutritional products and method of making same
US6132795A (en) * 1998-03-15 2000-10-17 Protein Technologies International, Inc. Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
US5994508A (en) * 1998-04-13 1999-11-30 Protein Technologies International, Inc. Isoflavone rich protein isolate and process for producing
US6083553A (en) * 1998-06-05 2000-07-04 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US6013771A (en) * 1998-06-09 2000-01-11 Protein Technologies International, Inc. Isoflavone rich protein isolate and process for producing

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219281A1 (en) * 2000-11-21 2004-11-04 Cargill, Incorporated Modified oilseed material
US20040131747A1 (en) * 2001-06-18 2004-07-08 Porter Michael A Modified oilseed material
US7429399B2 (en) 2001-06-18 2008-09-30 Solae, Llc Modified oilseed material

Also Published As

Publication number Publication date
US6680381B1 (en) 2004-01-20
US6706292B2 (en) 2004-03-16
EP1659119A1 (en) 2006-05-24
CA2207360C (en) 2002-08-13
AU720462B2 (en) 2000-06-01
RU2219785C2 (en) 2003-12-27
EP1659118A1 (en) 2006-05-24
KR100412117B1 (en) 2004-06-16
JPH1067770A (en) 1998-03-10
CN1195750C (en) 2005-04-06
US5990291A (en) 1999-11-23
TW474930B (en) 2002-02-01
US20030129263A1 (en) 2003-07-10
ATE302767T1 (en) 2005-09-15
US20020072591A1 (en) 2002-06-13
MX9704375A (en) 1998-04-30
EP0812837B8 (en) 2005-10-26
US6495141B2 (en) 2002-12-17
US20030118675A1 (en) 2003-06-26
DE69734042D1 (en) 2005-09-29
DE69734042T2 (en) 2006-06-14
US6323018B1 (en) 2001-11-27
US5821361A (en) 1998-10-13
US6664382B2 (en) 2003-12-16
BR9703526A (en) 1998-10-06
EP0812837A1 (en) 1997-12-17
ES2247617T3 (en) 2006-03-01
CN1174839A (en) 1998-03-04
CA2207360A1 (en) 1997-12-11
KR980002040A (en) 1998-03-30
EP0812837B1 (en) 2005-08-24
US5919921A (en) 1999-07-06
AU2481397A (en) 1997-12-18

Similar Documents

Publication Publication Date Title
US6706292B2 (en) Recovery of isoflavones from soy molasses
US5726034A (en) Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same
US6083553A (en) Recovery of isoflavones from soy molasses
EP0794960B1 (en) An aglucone isoflavone enriched vegetable protein concentrate and process for producing
EP0723536B1 (en) An aglucone isoflavone enriched vegetable protein whey, whey protein, and process for producing
US5827682A (en) Two-step conversion of vegetable protein isoflavone conjugates to aglucones
US5851792A (en) Aglucone isoflavone enriched vegetable protein whey whey protein material aglucone isoflavone material high genistein content material and high daidzein content material and process for producing the same from a vegetable protein whey
US6579561B2 (en) Aglucone isoflavone enriched vegetable flour and vegetable grit and process for making the same from a vegetable material containing isoflavone
KR100413025B1 (en) Aglucon isoflavone-enriched vegetable protein whey, whey protein material, aglucon isoflavone material, high zenistein content, high diad zein content and vegetable protein whey
US6521282B1 (en) Aglucone isoflavone enriched vegetable flour and grit
RU2309603C2 (en) Method for production of plant whey material enriched with aglucon isoflavone (variants), method for production of material with high content of genisteine and daidzeine
MXPA98000653A (en) Serum of vegetable protein enriched with aglucone isoflavone, serum protein material, aglucone isoflavone material, genistein high content and material with high content of daidzein, and procedure to produce them from a vege protein serum

Legal Events

Date Code Title Description
AS Assignment

Owner name: ARCHER-DANIELS-MIDLAND COMPANY, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SOLAE, LLC;REEL/FRAME:015810/0219

Effective date: 20050210

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION